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Abstract 
 
Omega 3 poly unsaturated fatty acids (n-3 PUFA) have been shown to protect against 
sudden cardiac death following myocardial infarction and reduce the risk of ventricular 
arrhythmias in patients with heart failure. At the inception of this study, there was one 
clinical study that reported n-3 PUFA supplementation reduced the risk of atrial 
fibrillation (AF) following CABG. As AF is a very common arrhythmia and as there are 
no safe and effective means of preventing AF, we designed this study to further validate 
the findings of the previous study in a more robust study design. In addition, this study 
also aimed to evaluate the cellular changes that underpin the beneficial anti-arrhythmic 
effect of n-3 PUFA. 
 
The outcome of this study shows that n-3 PUFA does not reduce the risk of AF following 
CABG. However, short term supplementation with n-3 PUFA reliably increases the 
membrane incorporation in phospholipids and results in alteration in the expression levels 
of cardiac calcium handling proteins phospholamban and ryanodine receptors. In addition, 
such incorporation in animal (rat) ventricular myocytes leads to changes in the rate of 
decay of the systolic calcium transient and an increase in the amplitude of the caffeine 
induced calcium transient thereby indicating a greater activity of SERCA. These findings 
needs further evaluation but is clearly interesting as the clinical situations where n-3 
PUFA have been shown to be anti-arrhythmic are situations where cellular calcium 
overload is the main mechanism of arrhythmogenesis.  
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1. INTRODUCTION  
1.1: Omega-3 poly unsaturated fatty acids  
1.1.1:  Fatty acid composition of human cardiac cell membranes 
Phospholipids are essential constituents of cell membranes. Changes in content and/or 
composition of these phospholipids are often associated with alterations in function and may 
even induce cell damage. Gudbjarnason et al were the first to report that alteration in the 
composition of fatty acids in membranes of cardiomyocytes was linked to cardio-vascular disease 
(1). In a study on 53 biopsy specimens of left ventricular myocardium collected during mitral 
valve replacement surgery, Rocquelin et al (2) reported the normal content and composition of 
various phospholipids in the human ventricular myocardium. Later, the same authors reported 
that the composition of fatty acids in the membranes of cardiomyocytes from various other parts 
of the heart such as the papillary muscles and right atrial appendage were similar (3) as shown in 
table-1 & table-2.  It is of particular interest to understand the normal composition of fatty acids 
in various phospholipids seen in human cardiomyocytes, so that a baseline value against which 
any alteration of content or composition can be compared. 
Table-1: Fatty Acid Composition of Human Heart Phospholipids- Data 
from 53 ventricular biopsy specimens (Rocquelin G et al2) 
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Table 2: Fatty acid composition of the main phospholipid classes in the 
human heart- Data from 19 biopsy specimens (Rocquelin G et al3) 
 
1.1.2: What are omega-3 fatty acids? 
The term omega-3 (or n-3) signifies that the first double bond exists as the third carbon-carbon 
bond from the terminal methyl end (n) of the carbon chain. They are termed poly unsaturated fatty 
acids as they have multiple double bonds and these are essential fatty acids in humans as humans 
cannot synthesize them. However, the plant n-3 poly unsaturated fatty acid (n-3 PUFA) α-
linolenic acid can be converted to other functionally important n-3 PUFA. The n-3 PUFA that are 
important in human nutrition are: α-linolenic acid (18:3, n−3; ALA), eicosapentaenoic acid (20:5, 
n−3; EPA), and docosahexaenoic acid (22:6, n−3; DHA). These three poly-unsaturates have 3, 5 
or 6 double bonds in a carbon chain consisting of 18, 20 or 22 carbon atoms, respectively. All 
double bonds are in the cis-configuration i.e. the two hydrogen atoms are on the same side of the 
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double bond, where they are more easily transformable. n-3 compounds are fragile and easily 
subject to transformation because the last double bond is geometrically and electrically more 
exposed, notably in the natural cis-configuration.  The metabolic pathway by which the plant n-3 
PUFA, ALA, can be converted to the more functionally relevant n-3 PUFA such as EPA and DHA 
are shown in figure-1.1. 
 
Figure1.1: Schematic diagram of the metabolic pathway of n-3 poly un-
saturated fatty acids  
 
  
 
 
The bio-chemical numbering of the carbon in fatty acids begins from the n (ω) carbon. Note that 
from the n end, the first double bond appears as the third carbon-carbon bond, hence the name "n-
3". This is explained by the fact that the “n” end is almost never changed during physiologic 
transformations in the human body, as it is more stable energetically. 
A recent work by McLennan et al (4) defines the baseline values of the total (in all 
the phospholipids) n-3 PUFA (EPA and DHA) in the human heart. This study evaluated 
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the fatty acid composition of myocardial samples from fresh explanted failing and donor 
hearts available through a heart transplant program. The study revealed that DHA was 
significantly higher than EPA in all chambers and the n-6 PUFA arachidonic acid (AA) 
and linoleic acid (LA) were the predominant PUFA. This study also reported that the 
DHA and EPA content, but no other PUFA, increased with age. Comparison of chambers 
showed total n-3 PUFA content of human atria were significantly higher than the 
ventricles while the total n-6 PUFA content was higher in the ventricles than in the atria. 
Thus, this study concluded that DHA is the principal n-3 PUFA in the human heart and it 
increases with age.  
 
1.1.3:  Omega-3 Vs Omega-6 Fatty acids 
There is considerable debate about the importance of the ratio of n3 and n-6 fatty acids in health 
and disease. The parent omega-6 fatty acid in human diet is linoleic acid (LA) present in 
abundance in plant oils. LA is then converted to arachidonic acid (AA) which is the precursor for 
the production of pro-inflammatory cytokines. LA is converted to AA by the action of the enzyme 
∆-6 desaturase, which is the same enzyme necessary to de-saturate alpha-linoleic acid (ALA), the 
parent compound of the omega-3 class. Thus LA and ALA compete for this desaturase. The 
presence of ALA in the diet can inhibit the conversion of the large amounts of LA in the Western 
diet, which contains high amounts of plant oils rich in omega-6 PUFAs (e.g. corn, safflower, and 
soybean oils) (5) . Thus the n-6: n-3 ratio will significantly influence the ratio of the ensuing 
eicosanoids with the n-6 derived compounds (e.g. prostaglandins, leukotrienes, thromboxanes) (6) 
being more inflammatory than those derived from n-3 PUFA. Studies have reported that a healthy 
ratio of n-6: n-3 ranges from 1:1 to 4:1 (7) While a typical western diets provide ratios of between 
10:1 and 30:1 with a substantially higher n-6 content (8). 
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1.1.4:  Sources of n-3 PUFA 
The plant source of n-3 PUFA is α-Linolenic acid (ALA), which is an organic compound found in 
many common vegetable oils. Oils derived from plant seeds are the richest sources of α-linolenic 
acid, notably those of rapeseed (canola), soybeans, walnuts, flaxseed (Linseed oil) and hemp. ALA 
can be converted to EPA and DHA in humans by the above reaction depicted in figure-1.1. 
However, the most widely available and a rich source of EPA and DHA is oily fish such as 
salmon, herring, mackerel, anchovies and sardines. Oils from these fish have a profile of around 
seven times as much n-3 as n-6. Other oily fish such as tuna also contain n-3 in lesser amounts. 
Although fish is a dietary source of n-3 fatty acids, fish do not synthesize them, they obtain them 
from the microalgae or plankton in their diet (9). 
One of the issues with consuming large amount of sea food as a source of   n-3 
PUFA is the risk of ingesting toxic substances particularly mercury. This is, however, 
present in negligible quantities in most commonly consumed salt water fish. The 
American Heart Association has published a summary of the n-3 PUFA content and the 
mercurial content of some of the commonly consumed fish (10) as shown in table 3.  
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Table-3: Omega-3 and Mercury Levels of commonly consumed sea food 
  Omega-3 fatty acids 
(grams/ 3-oz. serving) 
Mean mercury level in 
parts per million (ppm)
Canned tuna (light) 0.17–0.24 0.12 
Shrimp 0.29 Negligible 
Pollock 0.45 0.06 
Salmon (fresh, frozen) 1.1–1.9 0.01 
Cod 0.15–0.24 0.11 
Catfish 0.22–0.3 0.05 
Clams 0.25 Negligible 
Flounder or sole    0.48 0.05 
Crabs 0.27–0.40 0.06 
Scallops 0.18–0.34 0.05 
Fishes with the Highest Levels of Mercury (about 1 ppm) 
  
Omega-3 fatty acids 
(grams per 3-oz. 
serving) 
Mean mercury level in 
parts per million (ppm)
Tilefish (golden bass or 
golden snapper) 
0.90 1.45 
Shark 0.83 0.99 
Swordfish 0.97 0.97 
King mackerel 0.36 0.73  
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1.1.5:  Dietary intake Vs Supplements of n-3 PUFA 
Dietary intake is the most desirable way to increase n-3 PUFA intake, but in several clinical 
situations where n-3 PUFA have been shown to be beneficial in clinical studies, the doses used as 
supplements vary from 1 g per day of purified n-3 PUFA (OmacorTM-which contains 880mg of 
eicosapentaenoic acid and docosahexaenoic acid in a 1.2:1 ratio) to 2.5-4 grams/day. 1capsule of 
1g of Omacor contains n-3 PUFA which is equivalent to the fish oil present in about 55–85 g of 
fresh tuna, sardines, salmon, or trout, and 652 g of cod fish(11). Such high intakes are difficult to 
achieve in most parts of the world by dietary means alone. This finding is supported by a study by 
the EUROACTION study group (12). In this study, despite the fact that the active interventional 
approaches more than doubled the number of subjects consuming recommended levels of oily fish 
(8% Vs 17%), increase of long-term changes in diet was poor despite household re-education. 
Hence, an argument could be made for prescribing supplements in all clinical situations where a 
reliable increase in n-3 PUFA intake is indicated.  
 
1.1.6:  Omega-3 Index as a cardiac risk factor 
In a study by Harris and von Schacky (13), it was reported that the measure of the content of EPA 
and DHA in red blood cells, termed the omega-3 index, could be used as an indicator of n-3 PUFA 
intake, and thus target dietary modification or supplementation to achieve optimum values of this 
index. An omega-3 index of 8% or higher has been reported to be associated with the greatest 
cardiac protection, whereas an index of 4% or less gives the least cardiac protection. This 
approach, if validated in prospective clinical trials, would be a novel and potentially modifiable 
risk factor for death due to cardiac disease. 
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1.2: Atrial Fibrillation following cardiac surgery 
1.2.1 Atrial Fibrillation– a significant health care problem  
Atrial fibrillation (AF) is the most common sustained heart rhythm disturbance, affecting up to 
1 in 4 people at some stage of their life(14) and 3-5% of those over the age of 65 years(15,16). 
The presence of AF is associated with approximately a doubling of mortality risk after 
adjustment for co-existent cardiovascular risk factors(17), with the excess mortality attributable 
to thrombo-embolic stroke (18,19). A rapid heart rate response to exercise, beat-to-beat 
irregularity and loss of the atrial contribution to ventricular filling leads to diminished cardiac 
output and reduced exercise capacity. This condition is also a major drain on health care 
resources with approximately one third of all hospital admissions due to arrhythmias being 
directly related to AF(20). Current drug treatments are often ineffective, frequently causing 
adverse effects due mainly to their non selectivity of action and the potential risk of inducing 
more serious ventricular arrhythmias. It is therefore important to improve current 
understanding of the mechanisms causing this rhythm disturbance and to explore new 
therapeutic options that would be safer and effective. Fish oils (Eicasopentanoic acid (EPA) 
and Docasohexanoic acid (DHA)) have been shown to be beneficial in suppressing ventricular 
arrhythmias and their role in controlling atrial arrhythmias is actively being evaluated. 
However, their mode of action is unclear. This study aims to assess the clinical effect of fish 
oil supplementation on the incidence of atrial fibrillation following coronary artery bypass 
surgery and compare the electrophysiological properties of atrial myocytes obtained from the 
supplemented sub group of patients with matched controls. 
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1.2.2: AF following coronary artery bypass graft (CABG) surgery 
Atrial arrhythmias occur after cardiac surgery in 10% to 65% of patients(21,22) with variation 
according to patient profile, type of surgery, method of arrhythmia surveillance, and definition 
of arrhythmia. A meta-analysis of 24 trials(22) estimated the incidence of atrial fibrillation after 
coronary artery bypass surgery (CABG) at 26.7%. The highest incidence of atrial fibrillation is 
seen on postoperative days 2 to 3, with fewer patients developing atrial fibrillation either in the 
early postoperative period or 4 or more days after surgery (21,23-26). The development of atrial 
fibrillation is associated with a longer hospital stay and increased long-term mortality rate 
after adjustment for known associated risk factors(27). There are several preventive measures 
such as pre-operative use of anti-arrhythmic drugs, atrial pacing techniques etc that have been 
tried in clinical studies and have been shown to be of some benefit, but most of these therapies 
are of limited value in suppressing this arrhythmia and/or may be associated with significant 
adverse effects that they have not been absorbed into routine clinical practice. Hence there is a 
pressing need to identify an agent that would be effective and safe to use in this clinical setting 
in particular and in the management of all types of atrial fibrillation in general. 
 
1.2.3: Mechanisms of AF following CABG 
During atrial fibrillation, multiple re-entrant wavelets of excitation circulate throughout the 
atria. Recent work shows that these re-entrant wavelets may be triggered and /or driven by 
rapidly firing foci in the myocardium of the posterior left atrium and around the ostia of the 
pulmonary veins (28). Slowed atrial conduction velocities, altered refractory periods and in 
particular regional variations in these parameters provide the substrate which facilitates the 
persistence of atrial fibrillation (29,30). The risk factors for AF after coronary artery surgery 
appear to mirror those for spontaneous AF in the general population. Post-operative AF is 
associated with a prior history of the arrhythmia, is more common with advancing age, occurs 
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more frequently in men than in women and is associated with prolonged P wave duration on 
the surface ECG (indicating slowed atrial conduction)(31). Both AF and coronary artery disease 
are strongly associated with hypertension and male sex and therefore as a group, patients 
undergoing coronary artery surgery are at relatively high risk of developing this arrhythmia. 
Potential triggering factors after coronary artery surgery include increased sympathetic 
tone(32), ischaemia and trauma to the atrial myocardium, either directly as a result of surgical 
incisions or as a result of cardioplegic solutions(33-36). However since the incidence of atrial 
fibrillation is not consistently lower after “off-pump” cardiac surgery (with no 
cardiopulmonary bypass), which does not usually involve atrial incisions, it seems that atrial 
trauma may not play a major role as a cause of AF after CABG(37). The available evidence 
suggests that AF after CABG occurs as a result of increased triggering activity, probably 
related to high levels of sympathetic tone, in a group of patients who are already at risk for the 
arrhythmia. This is supported by the finding that beta-adrenergic blocking drugs can reduce 
the incidence AF in the post-operative period(38). In addition, there is increasing evidence to 
suggest that there is a role for mediators of inflammation in the occurrence of this arrhythmia 
particularly following cardiac surgery and this has been borne out by evidence of a significant 
difference in the levels of pro-inflammatory cytokines in the subset of patients who develop 
this arrhythmia.  
n-3 PUFA have been shown in clinical studies to have inhibitory effects on these 
pro-inflammatory cytokines. In summary, it is clearly evident that post-operative AF is an 
important clinical issue and there is an urgent need to identify an agent that will be of 
significant benefit in reducing the incidence of this common post operative arrhythmia 
while minimizing pro-arrhythmic tendencies. Fish oils may fit this description perfectly if 
the benefits shown in a small clinical trial(39) could be reproduced in a well designed, 
randomized,  blinded clinical trial. 
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1.2.4: AF following cardiac surgery as a “model”-Pros & Cons 
AF is a common complication following cardiac surgery and has significant morbidity and 
mortality associated with it. As this arrhythmia has such high incidence and it happens shortly 
after surgery, it lends itself as an excellent candidate to test the effect of an intervention on this 
common arrhythmia. In addition, any intervention that might reduce the risk of this arrhythmia 
is likely to be potentially useful and will have a direct clinical application in the pre-specified 
cohort of patients. However, using post operative AF as a surrogate to test the effect of an 
intervention on AF seen in other clinical settings has its own limitations. The main limitation 
relates to the fact that the cause of AF following CABG is multi-factorial and does not mimic 
the aetio-pathology of common clinical AF. There is a considerable amount of acute 
inflammation, direct myocardial injury due to atriotomy scar and use of multiple inotropic 
drugs which would have a substantial influence on the occurrence of this arrhythmia which is 
not common with other forms of clinical AF. The major advantage is the fact that atrial tissue 
(particularly right atrial tissue) is readily available during surgery thereby allowing the 
possibility of studying the cellular effects of an intervention and correlating it with the clinical 
outcome. 
 
1.3:  n-3 PUFA and Cardiac Arrhythmias 
1.3.1:  n-3 PUFA, Ventricular Arrhythmias & Sudden Cardiac Death 
Several observational and interventional studies report that high intakes of n-3 PUFA reduced 
risk of cardiovascular mortality and sudden cardiac death, especially in patients with previous 
myocardial infarction as shown in table-4 
Table 4: Summary of clinical studies on the effect of n-3 PUFA on 
cardiovascular mortality 
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Study Type Authors Publication details Main Findings
Observational Bang Ho et al Advances in Nutrition 
research-1980
Low rates of coronary heart disease (CHD) death among Greenland Eskimos 
consuming large amounts of seafood
Observational Albert CM et al.
(US Physicians Health Study).
JAMA-1998 Consumption of fish at least
once per week may reduce the risk of sudden cardiac death in men
Epidemiological Albert CM et al NEJM-2002 n–3 PUFA was associated with a reduced risk of sudden death among men 
without evidence of prior cardiovascular disease.
Epidemiological Lemaitre RN et al. 
(Cardiovascular Health Study)
AJCN-2003 Higher intake of n-3 PUFA may lower the risk of fatal ischemic heart 
disease in older adults. 
Epidemiological Streppel MT et al Eur Heart J-2008 Fatty-fish consumption lowered risk of SCD. There was no clear 
relationship between dose of n-3 PUFA and risk of SCD.
Clinical trial
(Post MI with dietary Intervention)
Burr M et al.
(DART study)
Lancet-1989 A modest intake of fatty fish (two or three portions per week) may reduce 
mortality in men who have recovered from MI.
Clinical trial
(Post MI with supplements)
GISSI-Prevenzione investigators Lancet-1999 Treatment with n-3 PUFA, lowered the risk of overall and cardiovascular 
death.
Clinical trial
(Stable CAD with dietary advice)
Burr M et al.
(DART-2 study)
EJCN-2003 Men advised to eat oily fish, and particularly those supplied with fish oil 
capsules, had a higher risk of cardiac death. Particulalry increased risk of 
SCD.
Clinical trial
(Secondary prevention in 
Haemodialysis patients, supplements)
Svensson M et al Clin J Am Soc Nephrol. 
2006 
n-3 PUFA supplementation did not reduce the total number of 
cardiovascular events and death in this high-risk population but significantly 
reduced the number of myocardial infarctions as a secondary outcome
Clinical trial
(Primary prevention with 
supplements)
Yokotama M et al. (JELIS study) Lancet-2007 No benefit in major coronary events in the primary prevention group, 
however, in the secondary prevention sub group, reduction in non-fatal 
coronary events but not cardiovascular mortality.
Clinical Trial
(Heart failure with supplements)
GISSI-HF investigators Lancet-2008 Reduction in all cause mortality but not SCD. However, considerable 
reduction in death due to presumed arrhythmias.
Meta analysis Bucher HC et al Am J Med.-2002 Dietary and non-dietary intake of n-3 PUFA reduces overall mortality, 
mortality due to MI, and sudden cardiac death in patients with coronary 
heart disease.
Systematic review Leon H et al BMJ-2009 n-3 PUFA supplementation was associated with reduction in deaths from 
cardiac causes but had no effect on arrhythmias or all cause mortality.
Systematic review Zhao YT et al Ann Med.-2009 n-3 PUFA has a beneficial effect on prevention of  SCD in patients with 
prior MI but not in patients who have angina.
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The most convincing evidence for a protective role of n-3 PUFA against sudden cardiac death 
comes from a sub-analysis of the GISSI-Prevenzione study (40) showing a significant reduction 
(p=0.04) within 4 months after a myocardial infarction. The presumed mechanism of such 
benefit would be a reduction in life threatening ventricular arrhythmias—the most common 
cause of sudden cardiac death in the early stages after a myocardial infarction. 
 
The role of n-3 PUFA in reduction of risk of sudden cardiac death in patients with non-
ischaemic cardiac disease is unknown and very little investigation has been done in this area. 
Investigators of a study (41) in a small number of patients with dilated cardiomyopathy reported 
beneficial alterations in known risk indicators for sudden cardiac death. In the GISSI Heart 
Failure study,(42) in which half of participants had heart failure attributable to non-ischaemic 
causes, sudden cardiac death was not greatly reduced. However, the greatest proportion of 
reduction in the primary endpoints of total mortality and hospital admission was attributed to a 
reduction in such events because of a presumed arrhythmic cause. 
 
Anti-arrhythmic potential of n-3 PUFA was tested in patients with an automatic 
implantable cardioverter defibrillator. Results of such studies have reported inconsistent 
results with one study showing marginal benefit,(43) another no effect,(44) and a third,(45) 
suggesting a possibility of increased risk of ventricular arrhythmic episodes in patients whose 
qualifying arrhythmia was ventricular tachycardia rather than ventricular fibrillation. An 
absence of overall effect was also reported in a meta-analysis(33) of these studies and in a 
systematic review of studies on mortality and arrhythmias, including a study of an appropriate 
implantable cardioverter defibrillator therapy as a marker of arrhythmic burden.(46) Moreover, 
one clinical study(48) reported that patients with coronary artery disease without previous 
myocardial infarction could have a heightened risk of sudden cardiac death with a high n-3 
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PUFA intake. Although this study had methodological limitations, evidence from studies in 
laboratory animals showed that n-3 PUFA in the presence of coronary ischaemia, without 
previous myocardial infarction, might predispose to an increased risk of ventricular 
arrhythmias (49). The conflicting finding and the apparent absence of benefit in studies 
designed to assess a direct anti-arrhythmic effect could be attributable to differences in the 
mechanisms of arrhythmia initiation in subsets within these study populations. 
 
 The two common mechanisms of initiation of life threatening ventricular 
arrhythmias are triggered activity and re-entry. Of the cellular electrophysiological effects 
of n-3 PUFA, shortening of action potential duration (50) and slowing of impulse 
conduction,(50) which would affect triggered activity with a favourable outcome, could 
promote re-entry in a susceptible substrate. Thus, a given patient could have either a 
lowered or raised risk of serious ventricular arrhythmias on the basis of the mechanism of 
initiation of the arrhythmia (51). Thus patients who have had a recent myocardial infarction 
and heart failure, with triggered activity as the predominant mechanism of arrhythmia 
initiation, would have a beneficial reduction in arrhythmias, whereas those with ischaemic 
heart disease in the absence of previous myocardial infarction and any other clinical 
situation in which the predominant mechanism of arrhythmia initiation is re-entry could 
be expected to have heightened arrhythmic risk. This finding is especially important 
because it suggests that patient selection could be a crucial issue before starting therapy 
with n-3 PUFA. 
 
 In experimental studies, mostly done in laboratory animals, researchers have reported 
that n-3 PUFA have several potential anti-arrhythmic effects (52,53) most notably a direct effect 
on cardiac ion channels. Initial data (53) from single-cell experiments with isolated 
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cardiomyocytes showed that acute application of purified n-3 PUFA had a profound inhibitory 
effect on sodium channels, reducing the peak sodium current by more than 50% and shifting 
the steady-state inactivation towards negative potentials, thus reducing excitability. This 
finding was supported by other similar studies (54,55) leading to the hypothesis that n-3 PUFA 
exert their predominant anti-arrhythmic effect by their inhibitory action on sodium channels. 
However, when cardiac cells with high membrane incorporation of n-3 PUFA, which was 
obtained from animals fed a diet fortified with fish oil, were studied, this effect was not 
consistently reported. Further studies in laboratory animals revealed that n-3 PUFA have a 
diverse range of effects on other ion channels, such as potassium channels, L-type calcium 
channels, sodium-calcium exchanger proteins, and calcium-handling proteins as shown in 
table-5.  
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Table 5: Summary of animal experiments on the effect of n-3 PUFA on 
ventricular arrhythmogenesis 
Study Type Authors Publication details Main Findings
Dietary supplementation in a whole animal 
model- Rat
McLennan P.L et al Am Heart J-1988 Incorporated tuna fish oil reduced vulnerability to both ischemic and reperfusion 
arrhythmias 
Dietary supplementation in a whole animal 
model- Rat
McLennan P.L et al Am J Clin Nutr.-1993 n-3 PUFA significantly reduced reperfusion arrhythmias. Fatal ventricular fibrillation 
(VF)  was significantly reduced in the n-3 PUFA group compared with saturated fat.
Dietary supplementation in a whole animal 
model- Marmoset monkey
McLennan P.L et al Am J Clin Nutr.-1993 n-3 PUFA reduced vulnerability of normal or ischemic myocardium to arrhythmias 
(measured as VF threshold) in a nonhuman primate.
Intra venous administration in a whole 
animal model- Dog
Billman G.E et al Circulation-1999 Intravenous administration of EPA or DHA prevented fatal ischemia-induced 
arrhythmias in an infarct model.
Acute application in ventricular myocytes-
Rat & Guinea pig
Macleod J.C et al Eur J Pharmacol-1998 Acute application of  EPA  resulted in shortening of action potential and increase in 
relative refractory period.
Dietary supplementation, incorporation in 
ventricular myocytes- Pig
Verkerk A.O Cardiovasc Res-2006 Shortening of action potential duration, inhibition of L type calcium current, reduced re-
opening of calcium channels at plateau potentials which could prevent triggered activity, 
no effect on transient outward current (Ito) but an increase in Ik1 and IkS pottasium currents 
and inhibition of sodium-calcium exchanger current.
Acute application in whole heart 
preparation- Rabbit
Dhein S Naunyn-Schmiedeberg's Arch Pharmacol -
2005 
Substantial reduction in velocity of impulse conduction (longitudinal) & less so with 
transverse conduction 
Acute application in isolated ventricular 
myocytes- Rat (Neonatal)
Xiao Y.F Proc Natl Acad Sci-1995 Substantial (51%) reduction in peak sodium current.
Acute application in isolated ventricular 
myocytes- Rat (Adult)
Leifert W.R J Physiol-1999 EPA & DHA shifted the voltage dependence of activation of the sodium channel to more 
positive potentials & this effect correlated with increase in membrane fluidity 
Dietary supplementation- Incorporation in 
ventricular myocytes- Rat (adult)
Leifert W.R J Nutr Biochem-2000 Incorporated n-3 PUFA had no effect on peak sodium current or the voltage dependant 
activation of sodium channels.
Acute application in isolated ventricular 
myocytes-Guinea pig
Ferrier G.R. Cardiovasc Res-2002 Suppression of L type calcium current while preserving myocardial function.
Acute application in isolated ventricular 
myocytes- Rat (Adult)
Bogdanov K.Y. Am J Physiol Heart Circ Physiol-1998 Inhibition of transient outward potasium current (Ito)
Acute application in cultured myocytes Xiao Y.F Biochem Biophys Res Commun-2004 Inhibition of outward & inward sodium-calcium exchanger current
Acute application in isolated ventricular 
myocytes- Rat (Adult)
Swan J.S. Cardiovasc Res-2003 Reduced frequency of spontaneous waves of calcium release (a function of sarcoplasmic 
reticulum), decreased diastolic calcium concentrations and increased calcium wave 
amplitudes and propagation
Dietary supplementation, incorporation in 
ventricular myocytes- Pig
Berecki G Heart Rhythm-2007 Myocytes from n-3 PUFA treated pigs displayed decreased SR calcium content, reduced 
L-type calcium current (I(Ca,L)), and less recruitment of the sodium-calcium  exchange 
current (I(NCX)) in response to norepinephrine. 
Dietary supplementation- Incorporation 
Langendorff-perfused hearts- Rabbit
Dujardin KS Am J Physiol Heart Circ Physiol-2008 DHA inhibited ultra fast sodium current  and reduced dofetilide-induced changes in 
triangulation, reverse use-dependence, instability, and dispersion of cardiac action 
potential (TRIaD).
Acute application in Vivo- Pericardial 
administration- Pig
Xiao YF Am J Physiol Heart Circ Physiol-2008 Pericardial infusion of  DHA reduced  malignant arrhythmias and infarct sizes in a 
porcine infarct model
Acute application in isolated ventricular 
myocytes- Heart failure-Human & Rabbits
Den Ruijter HM Circulation-2008 n-3 PUFA abolished triggered activity, reduced delayed afterdepolarizations & calcium 
after-transients,  reduced action potential shortening & intracellular calcium elevation in 
response to noradrenalin
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n-3 PUFA have also been shown to alter membrane fluidity(56), with consequent effects on ion 
transport. Thus, we would expect that the net effect would be derived from the sum of all these 
effects, on the basis of the relative concentrations and potencies of circulating free and 
incorporated n-3 PUFA, along with the state of excitability of the substrate and mechanism of 
arrhythmia initiation.  
 
 In addition to a direct anti-arrhythmic effect, other mechanisms that could explain 
some or all of the observed benefits from large clinical trials have been reported. These 
mechanisms are: beneficial modulation of the autonomic tone shown as improved heart rate 
variability;(57–59) reduction in basal heart rate,(60) probably due to an inhibitory effect on the 
pacemaker current (the funny current-If) in the sinus node cells; (61) and nutritional 
preconditioning similar to ischaemic preconditioning, restricting infarct size and reducing 
reperfusion-induced arrhythmias. (62) However, in the OMEGA multicentre study (63), no 
significant reduction in sudden cardiac death or coronary events were reported in a cohort of 
patients who had an optimum use of conventional therapy, such as β blockers, statins, and 
angiotensin converting enzyme inhibitors with a high rate of revascularisation procedures, 
which are used in standard clinical practice. Even though this study had a low power to detect 
such events, the possibility that n-3 PUFA might not confer additional benefits to those treated 
with optimum conventional medical therapy needs to be addressed, because previous studies 
were done in patients with suboptimum use of these agents as shown in table-6.  
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Trial Acronym & 
Year of 
publication
Anti-
platelet 
drugs
Cholesterol 
lowering 
agents
Beta-
Blockers
ACEI/ 
ARB
Relative risk 
reduction in CV 
mortality
DART
(1989)
10.2% NA 29.4% NA 31%
GISSI-
Prevenzione*
(1999)
87.9% 28.6% 41.2% 40.9% 17.7%
GISSI HF** 
(2008)
58% 22.6%*** 64.9% 93.5% 7.3%
OMEGA
(2010)
95% 94% 94% 83% No difference
Table-6: Comparison of concomitant drug therapy and cardiovascular (CV) 
mortality in randomised trials with n-3 PUFA.
ACEI: Angiotensin convertase inhibitor, ARB: Angiotensin receptor blocker, NA = Data not available, *All data derived from values 
at 6 month follow-up, when the reduction in CV mortality was significant, ** 50% of patients had non-ischaemic cardiomyopathy, 
***open-label use (one of the trial arm randomized to rosuvastatin).
 
1.3.2:   n-3 PUFA in Heart Failure and Arrhythmias 
Findings from epidemiological studies(64) have shown an inverse association between 
consumption of fish and risk of heart failure. In a large observational study with 60 000 
participants who were followed up for 13 years, investigators reported a reduction in death 
attributable to heart failure with increased fish intake. (65) The Atherosclerosis Risk in 
Communities (ARIC) study, (66) a prospective study of 3592 white men and women, reported 
for 14.2 years of follow-up that raised serum concentrations of n-3 PUFAs, especially 
docosahexaenoic acid, were associated with a lowered incidence of heart failure in women. 
The GISSI Prevenzione Investigators (67) reported that the observed reduction in sudden 
cardiac death in patients who had had myocardial infarction was most pronounced in those 
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with evidence of systolic left-ventricular dysfunction. In a large randomized study, GISSI HF 
Investigators (42) reported reductions in overall mortality and admissions in patients with New 
York Heart Association class II–IV heart failure with 1 g per day of EPA and DHA. Even 
though the observed benefit was modest, the fact that the benefits seen were incremental to 
optimum standard therapy lends support to use of n-3 PUFAs in management of heart failure. 
 
1.3.3:  n-3 PUFA and Atrial Arrhythmias 
Atrial arrhythmias, particularly Atrial fibrillation (AF) is the most common cardiac arrhythmia 
reported in clinical practice. In large epidemiological studies (68,69)  investigating the effect of 
fish intake on the risk of development of atrial fibrillation, researchers reported an absence of 
benefit, but in a prospective population-based study of adults 65 years and older investigators 
reported that risk of this disorder was lowered with consumption of grilled or baked fish,(70) 
with a possible dose-response effect that was confirmed by measurements of plasma  
concentrations of  EPA and DHA. In another observational study (71) in men older than 42 
years, high serum concentrations of DHA had a protective effect against atrial fibrillation 
during a follow-up of 17 years. 
 
 Data for the role of therapeutic supplementation of n-3 PUFA in management of atrial 
fibrillation are restricted to one study by Calo et al. (39) This study was conducted as a 
randomised, open-label study with the use of 2 grams/ day of concentrated n-3 PUFA 
(OmacorTM) for a minimum period of 5 days preceding CABG surgery and evaluated the 
incidence of new onset of AF following CABG as a primary outcome measure. In this study, 
160 patients undergoing cardiac surgery were either treated with standard therapy (79) or 
standard therapy plus 2g/day of n-3PUFA (81) and the incidence of AF following surgery was 
evaluated in the pre-operative period by a daily review of stored ECG traces in a bedside 
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monitor. In this study, post-operative AF developed in 27 patients of the control group 
(33.3%) and in 12 patients of the n-3 PUFA group (15.2%) (p = 0.013). Such beneficial effect 
was seen even in patients who received supplements for as little as 5 days prior to surgery. The 
mechanism of action of n-3 PUFA in reducing AF following cardiac surgery is not very clear 
but the cause and pathology of post-operative atrial fibrillation is unique with a significant role 
for inflammation in the causation of this arrhythmia.  
 
1.4:  Effects of n-3 PUFA on Ion Channels, Exchangers and 
Calcium Handling Proteins. 
1.4.1:  Putative Mechanisms of anti-arrhythmic action of n-3 PUFA  
A number of plausible mechanisms have been proposed to explain the anti-arrhythmic effects 
attributed to fish oils: structural, metabolic, autonomic, and electro-physiological. n-3 PUFA 
satisfy the structural requirements of anti-arrhythmic agents identified by in vitro studies to 
consist of a long acyl hydrocarbon tail, ≥2 unsaturated carbon-carbon double bonds, and a free 
carboxyl group at one end. Fatty acids are essential fuels for mechanical, electrical, and 
synthetic activities of the heart.72 EPA and DHA are preferentially bound at the sn-1 position 
in storage triglycerides, where lipases are most active and thus are mobilized more rapidly 
from adipose tissue stores in response to physiologic demand than are saturated fat and 
monounsaturated fat. n-3 PUFA are not active in triglyceride storage form and require 
phospholipases to be activated (73). Free fatty acids alter excitability and activity of various 
cardiac ion channels. The anti-arrhythmic properties of n-3 PUFA likely involve modulation 
of the biochemical processes underlying fatal ventricular arrhythmias (74). The mechanisms 
that have been proposed include direct effects on cardiac microsomal calcium/magnesium 
adenosine tri-phosphatase and voltage-gated ion channels, as demonstrated in cultured 
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neonatal cardiac myocytes. Also included may be effects on the inositol lipid cycle and cell 
signaling; on the cell membrane, via modification of membrane phospholipids; on gap 
junction; or anti-inflammatory effects mediated by eicosanoids. Support for a particular 
mechanism of action appears to depend on the type of study. While dietary studies support 
mechanisms mediated by changes in n-3 PUFA or their metabolites in plasma and vascular 
tissues, studies in isolated animal hearts and cultured neonatal cardiac myocytes support 
mechanisms related to direct effects on the electrophysiology of the heart. Although human 
data have not yielded consistent findings on whether n-3 PUFA influence cardiac arrhythmias 
through autonomic control, they have not ruled out the possibility of additional direct effects 
on ion channels in cardiomyocytes. Autonomic regulation involves control of inward sodium 
and calcium currents, which promote depolarization, and the outward potassium current, 
which opposes depolarization. n-3 PUFA have prevented or attenuated beta adrenergic agonist 
induced arrhythmias in cultured myocytes in the absence of confounders such as hormones 
and neurotransmitters.(75) 
While multitude of effects have been postulated, the direct effect of fish oils on ion channels 
(see later) have been extensively explored on animal studies and have yielded variable results 
based on the type of arrhythmia studied and the species of the animal used. 
 
1.4.2 Acute administration Vs Incorporated Fatty acids 
Increased consumption of fish oil leads to high levels of circulating n3-PUFAs in the blood (76) 
and also increase the amount of n3-PUFA incorporated into the sarcolemma of various 
tissues(77).  However, data on plasma levels of n3-PUFA after dietary interventions are scarce. 
In post menopausal women, fish oil supplements (2 g EPA and 1.4 g DHA) for 5 weeks 
increased plasma concentrations of EPA and DHA up to 0.5–0.7 mM(78). Animal studies have 
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shown that feeding a diet rich in n-3 PUFA for a period of about 8 weeks can increase the 
serum levels of EPA and DHA to 1.0-1.3mM(79). It is not clear if the circulating fatty acid is 
indeed free fatty acid as they could be bound to transport proteins (as most fatty acids are) and 
therefore their ready availability during an arrhythmia provoking situation such as acute 
myocardial infarction is not certain. Dietary administration of fish oil leads to the 
incorporation of n3-PUFAs into all the membranes including myocardial membranes of the 
heart. Several weeks after the start of the dietary intervention with fish oil, n3-PUFAs account 
for 25% of total lipids in the sarcolemma. Recent studies have focused on the relative 
contributions of circulating (presumably free) fatty acids and incorporated n3-PUFA to the 
beneficial effects on the clinical incidence of arrhythmias and myocardial cellular 
electrophysiology (80-82) This is particularly important while considering the beneficial effects 
of “therapy” with fish oil supplements.  
 
1.4.3 n-3 PUFA and cardiac membrane excitability 
Several studies have indicated that free long-chain polyunsaturated fatty acids (PUFA) EPA 
and DHA can markedly reduce the contraction rate of isolated, spontaneously beating 
cardiomyocytes and prevent or terminate the tachyarrhythmias and fibrillation induced by 
ouabain, high extra cellular calcium and β-adrenergic agonists(83-85). However, the mechanisms 
underlying the anti-arrhythmic effect of the fatty acids are far from clear. Kang et al examined 
the effects of various fatty acids on membrane electrophysiology in neonatal rat cardiac 
myocytes(86). They reported that application of free PUFA, but neither monounsaturated nor 
saturated fatty acids, significantly reduced membrane electrical excitability by increasing the 
threshold for action potential(more positive), the resting-membrane potential (more negative) 
and the refractory-period duration as shown in figure-1.2.  
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Figure 1.2: Effect of EPA on action potential generation in response to a fixed depolarizing 
impulse. Exposure to 10 µM EPA failed to elicit an action potential for the same depolarizing 
current and washing with BSA regenerated the action potential (Modified from Kang et al85).
 
 
Whilst such studies seem to indicate that there is a straightforward inhibitory effect on the 
electrical excitability of cardiac myocyte membranes, this effect is far from clear or 
straightforward. Other studies (87) have shown that this inhibitory effect is variable at different 
concentration levels and the optimal concentration to obtain an inhibitory effect depends on 
the species studied as shown in figure-1.3.  
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Figure 1. 3: Records of action potentials from a guinea-pig (left) and 
rat (right) ventricular myocyte showing  control action potential and 
the effects of the addition of 2, 5, 7.5 and 20 mM EPA. The effects of 
DHA are shown as open symbols and EPA acid as filled symbols.
The plot shows a reduction in the action potential duration of guinea-pig 
cells but a prolongation of the rat action  potential duration at low 
concentrations and a reduction in rat action potential duration at 
concentrations above 10 mM. (Modified from Macleod JC at al99)  
Such inhibitory effects on membrane excitability are often achieved by direct effects on the 
ion channels responsible for the initiation and conduction of an action potential. Hence the 
effects of n-3 PUFA on various cardiac ion channels have been studied on various animal 
models as detailed below.  
 
1.4.4:  n3-PUFA and the Sodium Current  
The cardiac sodium current (INa) is responsible for the upstroke of the action potential and 
plays an important role in impulse conduction. Studies on animal cells and cultured 
human cells have shown that the peak INa was significantly reduced after acute 
administration of EPA and DHA (5–10 μM) (88,89). In addition, the steady-state 
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inactivation of the current is shifted towards more negative potentials, without any 
significant change in activation properties(90,91). EPA also enhanced slow inactivation and 
markedly prolonged recovery from inactivation of human cardiac sodium channel- 
hH1α(89) Generally, n3-PUFAs showed higher affinity to block channels that were in the 
inactivated state compared to channels in closed or resting state(89). Interestingly, 
substitution of a single amino acid, asparagine with lysine at site 406 (N406K) in the D1-
S6 region of hH1α reduced the potency of EPA to inhibit INa . This has been taken as 
evidence that n-3 PUFA interact directly with the ion channel protein(92).  
As mentioned above, some studies have shown that acute application of n-3 PUFA 
does not affect the activation properties of the sodium channel(88,89). However, in adult rat 
ventricular myocytes, acute administration of n3-PUFA shifted the voltage dependence of 
activation of the cardiac sodium channel to more positive potentials(93). In this study, the 
effects of EPA and DHA on the cardiac sodium channel correlated with their ability to 
increase membrane fluidity(93). This variability highlights the species variability in the 
effect of free n-3 PUFA on voltage dependent sodium channels. 
In contrast with the acute effects due to direct application of free fatty acids, peak 
sodium current (INa)) was unaffected by incorporated n3-PUFA in ventricular myocytes 
isolated from animals fed a diet rich in fish oil(94,95). In these studies voltage dependence 
of activation remained unaltered, whereas a shift in inactivation towards more negative 
potentials was observed(94,95).  
In summary, acutely administered n3-PUFA reduces INa(88,89,93). This contributes to 
the observed reduction in excitability and to the slowing of ventricular conduction(96,97). 
However, incorporated n3-PUFAs do not alter INa (94,95). 
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1.4.5:  n-3 PUFA and the re-polarizing currents  
Early rapid repolarization or the notch of the action potential (phase 1) is caused by the 
transient outward current, carried by potassium ions (Ito1) and/or chloride ions (ICl(Ca) or 
Ito2). The slow and rapid components of the delayed rectifier current (IKs and IKr, 
respectively) are responsible for rapid repolarization (phase 3) of the action potential. The 
inward rectifier current (IK1) contributes to the terminal phase of repolarization and to the 
maintenance of the resting membrane potential.  
The Kv4.3 gene encodes a large proportion of the ion channel responsible for Ito1 and the 
n-3 PUFA, DHA has been shown to block the Kv4.3 current in a concentration dependent 
manner in a stable transfected mammalian cell line(98). Ito1 has also been shown to be 
inhibited following acute administration of EPA and DHA (IC50 < 10 μM) in rat and ferret 
ventricular myocytes(99,100). In the presence of the antioxidant alpha-tocopherol, this effect 
seems to be less pronounced, but still significant in rat ventricular myocytes101. However, 
incorporated n3-PUFAs did not alter Ito1 in ventricular myocytes isolated from rats fed a 
diet rich in fish oil(94).  
Ito is larger in subepicardial ventricular myocytes compared to mid- and endomyocardial 
ventricular myocytes and thereby contributes to transmural dispersion in repolarization102. 
Block of Ito1 would be expected to attenuate transmural dispersion of repolarization and 
thereby prevent re-entrant tachyarrhythmias(102) but so far the effects of fish oil on 
transmural dispersion of repolarization have not been investigated.  
IK has been shown to be decreased following acute administration of EPA and DHA in 
ferret cardiomyocytes(103). IK consists of two components IKr and IKs. Acutely 
administered DHA blocked the human ether-a-go-go-related gene (HERG) channel which 
encodes the pore-forming subunit of the ion channel carrying IKr in a time-, voltage- and 
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use-dependent manner(104). However, incorporated n3-PUFAs did not cause any change in 
IKr of pig ventricular myocytes(94).  
IKs has been studied in Xenopus oocytes upon expression of the channel pore-forming 
subunit, KvLQT1, in the presence or absence of the auxiliary subunit, hminK. IKs was 
enhanced by acute administration of DHA but not by EPA(105). Upon incorporation of n3-
PUFA, IKs was increased in pig ventricular myocytes(94).  
A decrease of IKr following acute administration of n3-PUFA may, at least in part, explain 
why n3-PUFA prolong the action potential as less repolarizing current is present during 
the repolarization phase of the action potential. On the other hand, augmentation of IKs by 
acutely administered n3-PUFA leads to increased repolarizing current during the 
repolarization phase of the action potential. Whether the observed changes in repolarizing 
potassium currents caused by n3-PUFA lead to action potential prolongation or shortening 
will largely depend on the delicate balance between these and other depolarizing and 
repolarizing currents, species-differences regarding channel protein expression and the 
concentration of free EPA and DHA.  
IK1 did not change upon acute administration of n3-PUFA in ferret cardiomyocytes(103). 
Incorporation of n3-PUFA resulted in an increase of IK1 in ventricular myocytes isolated 
from pigs fed a diet rich in fish oil(94). Increased IK1 by incorporated n3-PUFA contributes 
to the observed action potential shortening(94). In addition, an increase in IK1 may decrease 
excitability and thereby reduce DADs and triggered activity.  
The transient outward current is not always carried by potassium ions but is, in several 
species, carried by chloride ions (ICl(Ca))(106). Data on ICl(Ca) following acute administration 
of n3-PUFA are lacking. Incorporation of n3-PUFA into ventricular myocytes left ICl(Ca) 
unaltered(94). Other currents that affect action potential shape and duration, e.g. ultra-rapid 
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delayed rectifier K+ current, have not yet been investigated in the presence of (circulating 
or incorporated) n3-PUFA. 
In summary: (1). I to is inhibited by acute administration but not affected by incorporated 
n3-PUFAs. (2). I Kr is inhibited by acute administration and not altered by incorporation. 
Inhibition of   I Kr can lead to prolongation of action potential. (3). I Ks is enhanced both by 
acute administration and by incorporation. (4). I K1 is not altered by acute administration 
but enhanced by incorporation. This would have the effect of shortening of the action 
potential. 
In a clinical setting, following supplementation with n3-PUFA for a particular length of 
time, we can assume that the effects of incorporation would be reproducible. However, 
the availability of free fatty acids in the plasma (akin to acute administration of FFA) 
depends on various factors that come into play in vivo, the most important of which is 
likely to be the activity of phospholipases essential for the release of free fatty acids. 
 
1.4.6:  n3-PUFA and the calcium current  
It is known that the L-type calcium current (ICa,L) is the depolarizing current responsible 
for the plateau phase of the action potential and contributes to the duration of the 
ventricular action potential. Acute application of the n-3 PUFA on isolated animal 
ventricular cells (neonatal rat, adult rat and guinea pig) showed that ICa,L was suppressed 
in a concentration-dependent manner (IC50 < 10 μM) (107,108,109). Activation properties of 
ICa,L remained unchanged, and a negative shift of steady-state inactivation was observed 
in these studies. Interestingly, n3-PUFA reduced ICa,L, while preserving myocardial 
function (109).  
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Incorporation of n3-PUFAs into the sarcolemma also reduced ICa,L significantly 
while leaving activation properties unaltered(94). At plateau potentials, ‘reopening’ of the 
L-type calcium channel was reduced in ventricular myocytes with incorporated n3-PUFAs 
compared to the control myocytes(93). This may prevent early after depolarisations (EAD) 
and thereby triggered activity(94). Thus, acute administration of n3-PUFAs to ventricular 
myocytes reduces ICa,(108,109) and thereby lowers the plateau of the action potential. 
Incorporated n3-PUFAs also reduces ICa,L and, more importantly, inhibits ‘reopening’ of 
the calcium channel at plateau potentials. 
 
1.4.7:  n-3 PUFA and the sodium-calcium exchanger–(NCX) 
The sodium-calcium exchanger (NCX) exchanges 3 sodium ions for 1 calcium ion and is 
therefore electrogenic. It can generate inward or outward current and contributes to the 
shape and duration of the action potential. Outward and inward sodium-calcium 
exchanger current (INCX) was inhibited by acute administration of n3-PUFAs in HEK293t 
cells(110).  
Leifert et al. showed that a diet rich in fish oil increased the time constant of decay 
of Ca2+ transients in response to caffeine in isolated rat cardiomyocytes and suggested that 
NCX was involved(111). This finding was supported by experiments in ventricular 
myocytes, where both outward and inward INCX were reduced in the presence of 
incorporated n3-PUFA(94).  
Inhibition of INCX results in action potential shortening because less depolarizing 
current is available during the final repolarizing phase of the action potential(94,110). 
Furthermore, INCX contributes to DAD formation after spontaneous sarcoplasmic reticulum 
calcium release. Possibly, reduced INCX by both acute administration and incorporated n3-
 53
PUFAs reduce DADs and triggered activity. However, such an inhibitory effect has not been 
reproduced by other workers. A study by O`Neill et al(112) using the measurement of trans-
sarcolemmal calcium fluxes and intracellular calcium in rat ventricular myocytes showed that 
the application of EPA resulted in a significant decrease in the frequency of spontaneous 
calcium waves. The majority of this was due to inhibition of the Calcium release mechanism. 
In addition they also showed that EPA did not alter the rate of fall of calcium in the caffeine 
response (used as an indicator of surface membrane calcium efflux pathway activity). Thus, 
they concluded that the lower resting level of calcium observed in EPA is due to a lower 
influx of calcium across the surface membrane rather than increased activation of efflux 
pathways. This and other studies suggest that the calcium regulation mechanism rather than 
the NCX may be altered by PUFAs. 
 
1.4.8:  n-3 PUFA and calcium regulation  
Intracellular calcium handling plays an important role in the genesis of triggered activity(113). 
In experiments on rat ventricular myocytes, acute administration of EPA reduced the 
amplitude of  calcium transients and calcium sparks without modifying calcium spark 
kinetics(114). The frequency of spontaneous waves of calcium release was also diminished in 
the presence of EPA. This indicates that sarcoplasmic reticulum function is affected by acute 
administration of EPA. Additionally, EPA decreased diastolic calcium concentrations and 
imaging of calcium waves showed that EPA also increased calcium wave amplitudes and 
propagation velocity (115). Increased calcium wave amplitudes by EPA correlated with 
enhanced sarcoplasmic reticulum load in rat ventricular myocytes(116-117). It could therefore be 
concluded that n3-PUFA reduce sarcoplasmic reticulum calcium uptake and also inhibit 
calcium release. The potency of n3-PUFA to reduce open probability (Po) of RyR was 
demonstrated in isolated sarcoplasmic reticulum vesicles(116,118).  
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Spontaneous calcium release from the sarcoplasmic reticulum is the underlying 
mechanism for DAD-related arrhythmias in heart failure(119). Increased diastolic calcium 
levels have been shown to induce spontaneous calcium releases from the sarcoplasmic 
reticulum in a rabbit model of heart failure(120). In that model, diastolic and systolic [Ca2+]i 
levels were reduced after acute administration of EPA to isolated ventricular myocytes. 
Furthermore, spontaneous calcium releases and DADs were reduced by EPA after burst-
pacing in the presence of noradrenaline (121). In contrast, incorporated n3-PUFA did not cause 
any alterations in diastolic calcium or calcium transient amplitude in pig ventricular myocytes. 
In these animals, the duration of the calcium transient was shortened probably secondary to 
the shorter action potential recorded in these myocytes(94). Similar results were obtained in 
ventricular myocytes isolated from rats fed a diet rich in fish oil where calcium transients and 
diastolic calcium values remained unaltered in the presence of incorporated n3-PUFAs. In this 
study, sarcoplasmic reticulum calcium content was also unaffected by incorporated n3-
PUFAs(122).  
In summary, the effects of acute administration of n3-PUFAs on intracellular calcium 
handling are different from those with incorporated n3-PUFAs. Acute administration of n3-
PUFAs leads to a decrease in diastolic calcium concentration in rat ventricular myocytes and 
in ventricular myocytes isolated from rabbits with heart failure (115,117,121). Furthermore, EPA 
reduces spontaneous waves of  calcium release from the sarcoplasmic reticulum that underlie 
DAD-related arrhythmias (121). Therefore, acute administration of n3-PUFAs may reduce 
triggered activity based on spontaneous calcium releases and DADs.  
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1.4.9: n-3 PUFA and expression levels of cardiac ion channel proteins 
There is clear evidence that n-3 PUFA supplementation readily results in a significant 
incorporation on the cardiac cell membranes altering the composition of the membrane 
phospholipids. There is also evidence that n-3 PUFA influence the function of multiple cardiac 
membrane bound ion channels and may alter the fluidity of the membrane itself. However, to 
date, there is very little evidence about the effect of n-3 PUFA incorporation on the expression 
levels of any of the membrane bound proteins that influence cardiac arrhythmogenicity. 
Recent work by Guizy M et al(123) has reported that n-3 PUFA may exert a direct inhibitory 
effect on cardiac Kv1.5 ion channels without affecting the expression levels of these channels 
while Sarazzin et al (124) have reported a significant change in the expression levels of cardiac 
connexins (inter cellular communication channels) in a canine model of atrial fibrillation.  
 
1.5: AF and cardiac calcium handling 
Recent evidence indicates that altered intracellular calcium handling is an important 
pathophysiological mechanism in the initiation and sustenance of AF (184). It has been 
reported that increase in the atrial activation rate and the subsequent initial [Ca2+]i 
overload seen in  AF leads to further ‘remodelling’ of intracellular calcium handling. 
There is considerable interest in unravelling the contribution of altered intracellular 
calcium handling to different types of AF.  It is also noted that changes in intracellular 
calcium homeostasis preceding the onset of AF, in conditions which predispose to AF 
such as heart failure, appear to be different from changes in calcium handling developing 
after the onset of AF. Such alterations in intracellular calcium handling could have 
significant effect on three specific aspects of AF pathophysiology, (i) excitation–
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transcription coupling and calcium dependent signalling pathways, (ii) atrial contractile 
dysfunction, and (iii) arrhythmogenicity (184). 
 
1.5.1: Mechanisms involved in cardiac calcium cycling 
Activation of voltage-gated L-type calcium channels by membrane depolarization leads to 
the influx of a small amount of  calcium into the cardiac myocyte, which activates the 
release of larger quantities of calcium from the nearby calcium stores in the sarcoplasmic 
reticulum (SR). This amplification of the trigger calcium and its propagation results in a 
cell-wide transient increase in [Ca2+]i that initiates contraction as free calcium binds to the 
myofilaments. This calcium induced calcium release (CICR), which is characteristic for 
cardiac excitation–contraction (EC) coupling, is fundamentally the same in atrial and 
ventricular myocytes (185). Calcium homeostasis is restored and relaxation occurs as 
calcium is released from the myofilaments, pumped back into the SR by the SR Ca2+ 
ATPase and extruded from the cell by the sarcolemmal Na+/Ca2+ exchanger (NCX) as 
shown in figure 1.2. 
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Figure 1.4: Mechanisms involved in cardiac calcium cycling 
 
 
1.5.2: Diastolic calcium release and pro-arrhythmias 
In some disease conditions such as heart failure where there is a calcium overload in the 
SR, during diastole, small amounts of calcium is released locally from the SR which then 
leads to a small depolarising current due to the effect of the electrogenic sodium calcium 
exchanger pump which extrudes calcium from the cytosol. For each molecule of calcium 
extruded 3 molecules of sodium enter the cell and thus becomes electrogenic. When this 
propagates along the cell, the amount of calcium released increases exponentially due to 
the phenomenon of calcium induced calcium relase as described above and eventually a 
depolarising wave ensues which is termed delayed after depolarisation or DAD. Such 
diastolic depolarisations have been shown to cause ventricualr arrhythmias in patients 
with heart failure. There is increasing evidence that a simialr mechanism is active in the 
intiation of atrial fibrillation 186, 187.  
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1.5.3: Alteration in SR function and arrhythmogenic diastolic calcium 
release in AF 
As discussed above, alterations in claium handling and diastolic calcium release seem to 
play an important role in the initiaiton of AF. In that respect, there are two distict patterns 
of change in the cardiac calium handling seen in animal models of AF. In the rapid 
ventricular pacing-induced canine heart failure model of atrial fibrillation, it has been 
reported that SR calcium load is increased (186) and phosphorylation of PLB was increased, 
compatible with increased SR calcium reuptake. It has also been shown in the same model 
that RyR2 protein expression was reduced (186). However, in goats with chronic atrial 
dilatation, SR calcium load was decreased (188). In right atrial myocardium from dilated 
goat atria, PLB phosphorylation was reduced, which is compatible with decreased 
SERCA2a function. In addiiton, in the same model, hyperphosphorylation of RyR2 , a 
mechanism that is thought to increase the channels' open probability was also seen (189,190) 
consistent with diastolic Ca2+ ‘leak’ from the SR. Thus, in chronic atrial dilatation in goats, 
reduced SR Calcium load might be due to increased loss and reduced reuptake of calcium 
into the SR due to reduced SERCA activity and increased open probability of RYR2.  
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1.5.4: Effect of n-3 PUFA on cardiac calcium  regulation 
Cellular experiments have consistently shown that acute administration of n3-PUFAs 
leads to action potential shortening resulting from its inhibitory effect on ionic 
currents such as sodium current (INa) and L-type calcium current (ICa,L) (99,100,108) A shorter 
action potential prevents calcium overload and DADs as a result of the longer diastolic 
interval and increased time for calcium removal (191). Furthermore, acute application of n-
3-PUFAs to normal myocytes also decreases calcium transients, inhibits calcium sparks, 
and reduces spontaneous calcium release from the SR (112,115). Recently Den Ruijter et al 
reported that acute application of EPA and DHA to isolated ventricular myocytes from a 
rabbit model of heart failure and human explanted (heart failure) heart shows that there is 
a significant reduction in both systolic and diastolic levels of calcium with evidence of 
inhibition of triggered activity. This effect could have a significant anti-arrhythmic 
property in heart failure. 
 
1.6: Summary of current evidence 
Animal experiments and clinical studies have reported that n-3 PUFA may have a protective 
effect against life threatening ventricular arrhythmias following myocardial infarction and 
heart failure. However, the effect of n-3 PUFA on atrial arrhythmias is less well understood. 
There is some suggestion that n-3 PUFA may protect against AF following CABG but this 
data is derived solely from one open-label clinical study, which by nature of the study design 
allows for a potential for bias. There is considerable volume of data from animal studies 
showing that n-3 PUFA have a multitude of effects on cardiac ion channels all of which could 
be potentially anti-arrhythmic but the mode of action of n-3 PUFA to achieve such an effect is 
still unclear. There is very little data on the influence of membrane incorporation of n-3 PUFA 
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on the expression levels of these ion channel proteins. Moreover, the clinical benefit of 
reduced risk of sudden death has been shown predominantly following an MI and in patients 
with heart failure. In both these situations, the primary arrhythmogenic mechanism is 
alteration in cellular calcium handling. Recent evidence suggests that altered calcium 
homeostasis may have a role in the initiation of atrial fibrillation. However, the effect of n-3 
PUFA on cardiac calcium handling has not been adequately investigated. Hence this study will 
focus on the effect of membrane incorporation of n-3 PUFA on atrial arrhythmias and the 
cellular effect on calcium handling proteins in humans.  
 
1.7:  Research hypotheses 
• Oral supplementation of purified n-3 PUFA (OmacorTM) (presented as 1g capsules 
containing 88% n-3  PUFA) to patients undergoing coronary artery bypass graft 
(CABG) surgery will lead to a measurable change in the membrane composition of 
fatty acids in cardiomyocytes and would influence the incidence of atrial fibrillation 
following coronary artery bypass surgery. 
• Incorporation of n-3 PUFA on cardiomyocytes of the atrial appendage tissue (obtained 
during CABG surgery) will lead to changes in the expression levels of calcium 
handling proteins and/or other ion channels and transporters. This alteration in 
expression will lead to a measurable change in the function of the relevant protein. 
• These changes could be initially evaluated by the use of quantitative PCR technique 
and based on the results of this less specific but more sensitive technique (used as a 
form of screening technique) a focused evaluation of the relevant protein/s can be 
performed to elucidate the effect of n-3 PUFA on cellular calcium handling and/or 
other ion channels and transporters in humans.  
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CHAPTER-2: MATERIALS AND METHODS  
2.1: Clinical methods 
2.1.1: Study design 
This study was designed as a single-center, randomized, double-blind, placebo controlled 
clinical trial carried out in the department of cardiology and cardiothoracic surgery in 
University Hospital of South Manchester (UHSM) Wythenshawe, Manchester.  The study was 
primarily designed to test the hypothesis that n-3 PUFA supplementation would reduce the 
risk of AF after CABG. The major limitations of previous studies evaluating various 
interventions to reduce the risk of AF following cardiac surgery and most clinical studies 
evaluating the anti-arrhythmic potential of n-3 PUFA are the lack of robust monitoring for AF 
in the former and the lack of objective evidence of levels of n-3 PUFA in the latter, along with 
a possible confounding effect of dietary PUFA intake on these levels. We sought to address 
these issues by means of continuous monitoring of AF in the postoperative period for 5 days 
and by quantifying serum, peripheral blood mononuclear cell membrane and tissue levels of n-
3 PUFA to assess if therapy had indeed altered the levels in these cell membranes, along with 
a food frequency questionnaire to estimate the dietary intake of n-3 PUFA. Such direct 
estimation of cardiac tissue levels of n-3 PUFA and direct correlation with clinical outcome 
has not been done in any of the previous clinical studies on this subject. We also estimated 
serum levels of C-reactive protein (CRP) as a marker of systemic inflammation because 
systemic inflammation has been suspected to play a role in the initiation of AF after 
CABG(21,125) and n-3 PUFA have been shown to possess anti-inflammatory properties(126). 
 
The study protocol was approved (under the title- How does fish oil supplementation 
reduce risk of atrial fibrillation following coronary bypass surgery?- A cellular study) by the 
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Medicines and Healthcare Regulatory Agency of the United Kingdom and registered with the 
European Clinical Trials database (EudraCT) as a clinical trial of an investigational medicinal 
product (Appendix-1).  The conduct of the study was approved by the Trent Multi-center 
Research Ethics Committee (Aappendix-2). The study was sponsored and approved by the 
R&D department of the University Hospital of South Manchester, Wythenshawe (Appendix-
3). The clinical trial was supervised by Dr. Neil C Davidson, Consultant Cardiologist, UHSM, 
Wythenshawe, as the principal investigator. A subsequent substantial amendment was made 
and approved by the Trent ethics committee to enable changes to the cellular aspect of the 
study to be made (Appendix-4). A data monitoring committee was formed consisting 2 
independent cardiologists and a statistician from within our institution with a view to 
monitoring data at 18 months of the conduct of the study and at study completion.  
 
2.1.2: Sample size calculation 
The average incidence of AF after CABG in UHSM, Wythenshawe is approximately 50%, 
which is within the range of previously reported values(21,22). Hence, sample size was 
calculated with an expected incidence of postoperative AF of 50% in the control group and a 
relative risk reduction of 55% by n-3 PUFA in accordance with the study by Calo et al(39).  
This gave a sample size of 54 patients in each group (108 in all), with 80% power to detect a 
significant difference using simple χ2 test with the conventional 5% significance level. 
 
2.1.3: Patient recruitment  
Inclusion Criteria:  
• All patients over the age of 18 years, who were to undergo elective isolated CABG on 
cardiopulmonary bypass at University Hospital of South Manchester, UK. 
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Exclusion Criteria:   
• Patients with previous or current history of any atrial arrhythmia. 
• Patients who were taking any class 1 or class 3 anti-arrhythmic drugs (Vaughan-
Williams classification) 
• Patients who were taking or had been taking within the previous 3 months fish oil 
supplements.  
 
Screening and Enrolment: Patients were identified by screening the cardiac surgical waiting 
list and those found eligible were sent a copy of the patient information leaflet (version-4) 
Appendix-5) along with the appointment letter for their pre-admission clinic. This enabled the 
patients to read through the details of the study and gave them adequate opportunity to raise 
any queries that they might have when meeting the researcher in person prior to study 
enrollment. Patients, who were willing to participate in the study, were enrolled during a 
preadmission clinic visit, which typically took place 1 to 3 weeks before surgery. At 
enrolment, all participants gave written informed consent to take part in the study. A copy of 
the consent form is shown as Appendix-6. 
Study enrolment commenced in June 2007 and was completed in January 2009. A total 
of 108 patients were enrolled of 343 eligible patients as shown in Figure-2.1. Consecutive 
patients were randomly assigned, in a double-blind fashion,  and were advised to take 2x1g 
capsules of (2 g/d) a commercially available n-3 PUFA preparation (Omacor; Pronova 
Biopharma, Lysaker, Norway) providing 85% to 88% EPA+DHA as ethyl esters and in a ratio 
of 1.2:1 in addition to standard care (active treatment group) or 2x1g capsules (2g/d)  placebo 
(olive oil) along with standard care (placebo group). Both n-3 PUFA and placebo were 
presented in identical 1-g capsules. Random assignment was based on a computer generated 
randomization list obtained using blocks of size 4. 
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Figure-2.1: Clinical Trial Flow Chart
 
2.1.4: Venous blood sample collection and processing 
Upon enrollment and random assignment, a peripheral venous blood sample was 
collected in heparinised vacutainers for preparation of serum and PBMC. Whole blood was 
collected in two 10mls vacutainers (one with heparin for PBMC separation) and one of them 
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centrifuged at 10000 rpm for 10 minutes to separate serum. The supernatant serum was then 
transferred into an eppendorf tube using a sterile Pasteur pipette. The other blood sample was 
used to separate PBMC using Ficoll gradient. The method of separating PBMC is briefly as 
follows: Two 20ml test tubes were filled with 10mls of Ficoll-Paque Plus solution each. 10 ml 
of heparinised blood was gently pipetted on top of Ficoll-Paque Plus and centrifuged for 20 
minutes at 2000 rpm (no brake). The two white blood cell ring fractions were transferred to a 
new 20 ml test tube using a sterile Pasteur pipette and the volume was adjusted to 10 ml by 
adding PBS which was again centrifuged at 1700 rpm. The supernatant was discarded the 
pellet of PBMC was re-suspended in 3 ml of PBMC which was transferred to Eppendorf 
tubes. Both the serum and PBMC samples were labelled with anonymised identifier code 
numbers and stored at -80°C for future analysis. 
 
2.1.5: Echocardiographic assessment 
All patients had a 2D echo-cardiographic evaluation for left ventricular (LV) systolic 
function and left atrial (LA) size, using standardized measurements. Patients were deemed to 
have LV dysfunction if they had an LV ejection fraction (modified Simpson’s method) ≤55% 
and significant atrial dilation if the atrial AP diameter was ≥2.3 cm/m2 body surface area.  
 
2.1.6: CABG surgery and tissue processing  
All participants had CABG surgery using a midline sternotomy incision on 
cardiopulmonary bypass. On the day of surgery, all patients had a second venous blood 
sampling and serum and PBMC was prepared as before. During surgery, a small sample 
of tissue from the right atrial appendage was obtained. This tissue was immediately 
washed free of blood and dissected into 3 pieces and 2 of the 3 pieces were immediately 
snap frozen by immersion in liquid nitrogen, labelled with anonymised sample identifier 
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codes and stored at -80°C for future use in molecular biological studies. The third piece of 
tissue was immediately processed by the researcher in an attempt to isolate human atrial 
cells with a view to performing electropysiological studies as detailed below.  
 
2.1.7: Dietary intake of n-3 PUFA 
On recruitment, all patients were provided with a self-administered food frequency 
questionnaire listing commonly consumed food items that are considered to be sources of 
marine n-3 fatty acids (Appendix-7). All portions were clearly defined and when 
participants had consumed but less than a defined portion they could choose to enter half 
a portion so that an accurate estimate of the dietary intake of n-3 PUFA was available for 
all participants at baseline. Based on the information provided in this questionnaire, their 
weekly intake of n-3 PUFA was estimated using pre-defined values that reflect the 
quantity of n-3 PUFA present in a portion of a specified food item. All 103 patients who 
completed the study provided a valid response to this questionnaire based on which a 
reliable estimate of the weekly intake of n-3 PUFA in all the study participants was 
calculated at baseline. All study participants were advised not to change their dietary 
habits during the study period. 
 
2.1.8: Post-operative arrhythmia monitoring 
A heart rhythm monitor (Lifecard CF digital Holter recorder; Space Labs Healthcare, 
Wash) was attached to the patient’s chest in the immediate post-operative period in the 
cardiac intensive care to continuously record 2-lead ECG data for 5 postoperative days. If 
patients stayed in the hospital for longer than 5 days, a daily ECG was performed along 
with a daily clinical follow-up by the researcher. On completion of recording, data from 
the Lifecard monitor was downloaded onto a Delmar Reynolds computer system (Space 
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Labs Healthcare) and archived to a disk. At the end of the study, these data were analyzed 
by 2 independent experts (Researcher and a senior ECG technician) using an automated 
arrhythmia diagnostic system (Pathfinder Digital; Space Labs Healthcare). 
The system divides the continuous ECG recording into 24-hour segments. Briefly, 
the methods of AF identification were as follows: ECG recordings were loaded and 
appropriate program sensitivity and detection were checked. Interpretation of whether any 
arrhythmia existed on each day was performed by analysis of peaks/troughs of the 24-
hour trend graphs of heart rate, N-N intervals (the time intervals between consecutive 
normal beats, reflecting underlying sinus rhythm), and sNN50 (number of pairs of 
adjacent R-R intervals differing by ≥50 ms). If no arrhythmia was detected, it was 
recorded as 0 incidence of AF and 0% of recording spent in AF. If the interpretation was 
inconclusive or if an arrhythmia was thought to have occurred, then the entire 24-hour 
recording was scanned at an appropriate speed and episodes of AF ≥30 seconds were 
manually identified and appropriately labeled. The program then calculated the number of 
AF episodes marked and the percentage of recording in AF. All 12-lead ECGs were 
manually analyzed by the researcher.  
 
2.1.9: Therapy, monitoring and follow-up after CABG 
Patients continued to take n-3 PUFA or placebo in the postoperative period until 
discharge from the hospital. If patients were unable to take the capsules orally (3 patients 
in the active treatment arm and 2 patients in the control arm) in the immediate 
postoperative period, the contents of the capsules were mixed with the naso-gastric feed; 
this was carried out exclusively in the intensive care unit by the nurse in charge of patient 
care, without compromising the blinding process. A further blood sample was collected 
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on the 3rd postoperative day (48 to 72 hours after completion of surgery); serum was 
prepared and used to measure concentrations of CRP. 
Formal participation in the study ended at hospital discharge. However, any 
hospital admission in the 4 weeks after surgery was evaluated for potential study-related 
complications. 
 
2.1.10: Clinical outcome measures 
The primary outcome measure was any AF ≥30 seconds in the Lifecard monitor 
recordings. Secondary outcomes were clinically recognized AF (as documented by the 
treating clinicians in the patients clinical records), AF burden (defined as the percent of 
time a given patient is in AF), length of stay in the hospital, and length of stay in the 
intensive care or high-dependency care unit. In addition CRP levels were measured to 
assess influence of n-3 PUFA on inflammatory markers and consequent effect on the 
incidence of AF following CABG surgery.  
 
2.1.11: Clinical indices influencing risk of arrhythmias 
There are several ECG markers which have been reported to be useful in predicting the 
risk of development of atrial and ventricular arrhythmias. One of the consistent parameter 
that has been associated with a risk of developing atrial arrhythmia is P-wave dispersion 
(PWD) in a standard 12 lead surface ECG. This is the difference between the maximum 
and minimum P-wave duration measured in all the 12 leads. It has been suggested that 
PWD is a measure of the degree of heterogeneity in conduction in the human atrium and 
larger PWD may pre-dispose an individual to higher risk of atrial arrhythmias (192). Pre-
operative PWD has been reported to be useful in predicting post operative AF following 
CABG. In addition, n-3 PUFA have been shown to alter expression levels of connexins in 
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canine atrium and may have an influence on PWD. Hence we measured this variable in all 
the participants pre- and post supplementation. Another important ECG variable that 
predicts risk of ventricular arrhtymia is heart rate variability (HRV). HRV is a measure of 
the degree of autonomic tone with lower HRV indicating poor autonomic balance and 
higher risk of arrhythmias. n-3 PUFA have been reported to influence the autonomic 
nervous system in a favourable way with lower resting heart rate and an improved HRV 
particularly in diabetic subjects. Hence we also measured HRV in this study-following n-
3 PUFA supplementation- on day 3 following CABG.   
 
1) P-wave dispersion (PWD) in 12 lead ECG: Standard supine 12 lead ECGs (filter 
range, 0.15 to 100Hz, AC filter  60Hz, 25mm/s, 10mm/mV) were obtained for all patients 
at recruitment (baseline) and the day before surgery (post supplementation). The effect of 
n-3 PUFA supplementation on some recognised markers of atrial arrhythmias was 
evaluated by analysing these ECGs by the following method. All ECGs were scanned and 
magnified 200% to fit the computer screen. A digital calliper was used to make accurate 
measurement of the relevant intervals. 2 independent observers (the researcher and a 
senior ECG technician) reported on these values. Both observers were blinded to the 
therapy (n-3 PUFA or Placebo) that the patients received at the time of analysis. Reports 
on P wave duration on each lead for a given 12 lead ECG was generated by each observer 
by taking an average of 3 complexes in each lead. This generated 2 sets of values for P 
wave duration for each lead in a given 12 lead ECG. When there was more than 5 ms 
difference between the values from both the observers, measurements were repeated by 
both observers on that given lead and compared. A mean of the 2 values were obtained for 
each lead and based on these values, P-max and P-min were calculated as the maximum P 
wave duration and minimum P wave duration respectively in a given 12 lead ECG. P 
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wave dispersion (PWD) was calculated as the difference between P-max and P-min. 
These values were reported for all the study participants at baseline and following n-3 
PUFA supplementation. At study completion and un-blinding, the PWD values between 
the two groups were compared to evaluate the effect of n-3 PUFA on this index of atrial 
arrhythmogenesis. 
 
2) Heart rate variability (HRV): Day 3 of each patient’s ECG recording was analysed 
for 24-hour time and frequency domain HRV parameters using a commercial software 
package designed for this purpose (Pathfinder HRV Tools software package).  Additional 
single hour frequency domain measures were taken from the day 3 data for one hour prior 
to AF onset, or between 12pm-1pm if no AF had occurred.  Episodes of ECG of non-
sinus rhythm >10 seconds were marked and excluded from system calculations of HRV 
measures. The time and frequency domain parameters collected are summarised in table-
7, and are as recommended by ESC and NASPE (Heart Rate Variability Task Force 
1996)127.  When calculating the HRV parameters only normal-to-normal (NN) intervals 
were used. Thus, both ectopic coupling intervals and post-ectopic pauses were excluded 
from the measurements. 
The time domain measures determine the variations in successive heart beats 
allowing temporal analysis.  They can be thought of as follows: SDNNi estimates the 
overall HRV and mirrors circadian rhythm; SDANN estimates the long term components 
of HRV; RMSSD estimates the short term components of HRV and higher values indicate 
vagal activity. 
Power spectral analysis provides information of how power (i.e. variance) 
distributes as a function of frequency.  The frequency domain measures are less well 
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defined but may be thought of in the following terms; nHF represents vagal activity; nLF 
may mirror sympathetic modulation and LF/HF reflects sympathovagal balance. 
Table-7: Description of HRV measurements 
HRV Measurement     Description 
Time Domain Measures 
SDNNi (ms) Standard deviation of the NN intervals in every 5 mins, a 
single 24hr value is reported 
SDANN (ms) Standard deviation of average NN interval for every hour, a 
24hr value is reported 
RMSSD (ms) Square-root of the mean of the sum of all squares of 
differences 
Frequency Domain Measures 
nLF Low frequency power (0.04-0.15Hz) in normalised units 
nHF High frequency power (0.15-0.40Hz) in normalised units 
LF/HF   Ratio of LF/HF 
 
 
2.1.12: Estimation of serum and tissue levels of n-3 PUFA  
All serum and tissue samples were stored at -80°C. Samples for fatty acid analysis were 
later transported on dry ice to the University of Southampton, where they were maintained 
at-80°C until analysis. Serum CRP concentrations were measured by a previously 
validated technique of particle-enhanced immuno-turbidimetric assay (Modular P600, 
Roche Diagnostics, Mannheim, Germany) using ruthenium electro-chemiluminescence to 
obtain a signal.128,129 The fatty acid compositions of serum phosphatidyl-choline (PC), the 
major circulating phospholipid, and of atrial tissue PC and phosphatidyl-ethanolamine 
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(PE) were determined using gas chromatography. In brief, total lipid was extracted from 
serum or homogenized atrial tissue using chloroform/methanol (2:1 vol/vol). PC and for 
atrial tissue PE were isolated from the total lipid extract using aminopropylsilica solid-
phase extraction columns; PC was eluted with chloroform/methanol (3:2 vol/vol) and PE 
with methanol. Fatty acid methyl esters were prepared from the isolated PC and PE 
fractions by incubation with methanol containing 2% sulfuric acid for 2 hours at 50°C.  
Fatty acid methyl esters were isolated by solvent extraction, dried, and separated 
in a gas chromatograph (model 6890; Hewlett-Packard, Avondale, PA) fitted with a 30m 
x 0.32 mm BPX70 capillary column with a film thickness of 0.25 mm. Helium at 1.0 
ml/min was used as the carrier gas and the split-splitless injector was used with a split-
splitless ratio of 20:1. Injector and detector temperatures were 275°C. The column oven 
temperature remained at 170°C for 12 min after sample injection and was programmed to 
then increase to 210 °C in increments of 5°C/min and then remain at 210°C for 15 min. 
The separation was recorded with HP GC CHEM STATION software (Hewlett Packard). 
Fatty acid methyl esters were identified by comparison with standards run previously and 
data are expressed as percentage of total fatty acids present in the PC or PE fraction. 
 
2.1.13: Statistical analysis of clinical data 
All data were analyzed by a qualified statistician. All analyses were done on an intention-
to-treat basis. Comparisons between groups were made using χ2, Student t test, and 
Mann–Whitney U tests as appropriate. Differences in AF-free survival were assessed 
using Kaplan–Meier analysis. Cox proportional hazards regression analysis was 
performed to assess the confounding effect of baseline patient characteristics. Variable 
selection was done using a stepwise selection process. All analysis was carried out using 
SPSS Version 15.0. In all cases, a value of P<0.05 was taken to indicate statistical 
 74
significance. All continuous variables are reported as median with interquartile ranges 
(25th to 75th percentiles). 
 
2.2: Quantitative PCR 
The high sensitivity of Quantitaive PCR (qPCR) makes it an ideal technique to detect 
expression of ion channels, transporters and calcium handling proteins as the mRNA 
expression of these channels in cardiomyocyte is considered to be relatively low 
(compared to skeletal muscle, CNS tissue etc). In addition, this technique can be used to 
detect large number of target mRNAs quantitatively in small tissue samples. Most 
reagents for qPCR are available as commercial kits. The main principle of PCR relies on 
exponentially amplifying cDNA, obtained from mRNA by a reverse transcription 
reaction, using a polymerase chain reaction. Recent technological improvements and the 
use of fluorescent systems enable amplification to be recorded throughout the time course 
of the PCR. This allows for small differences in the abundance of the initial gene 
transcript to be accurately estimated. Thus all qPCR involves the use of fluorescence to 
detect the threshold cycle (Ct) during PCR when the level of fluorescence gives signal 
over the background and is in the linear portion of the amplified curve. SYBR Green is a 
dye that intercalates with double-stranded DNA. This intercalation causes the SYBR to 
fluoresce. The qPCR machine detects the fluorescence and software calculates Ct values 
from the intensity of the fluorescence. Steps followed in this the qPCR procedure were as 
follows 
 (1)Total RNA isolation from the right atrial appendage tissue  
(2) Determination of the quantity and quality of the RNA isolated 
(3) cDNA synthesis- Reverse Transcription 
(4) qPCR with primers specific for the target mRNA  
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(5) Calculation of the relative abundance of the target mRNA. 
 
2.2.1: Total RNA isolation from the right atrial appendage tissue 
The sample of frozen right atrial appendage tissue was cut in 10-20 μm sections on a 
cryostat and used for total RNA isolation using a RNeasy Micro Kit (Qiagen). 155 μl of 
lysis buffer (miRVana) was added to the tissue sections and immediately homogenized 
with a polytron at full speed for 2 minutes. This ensured quick and efficient denaturation 
of RNases. RNase free water was then added to the mixture (295µl) followed by addition 
of proteinase K (5μl) (Quiagen). The mixture was incubated in a water bath at 55°C for 10 
minutes until a clear solution was visible. This allowed a vast majority of proteins to be 
digested. The sample was then centrifuged at 13000 rpm for 5 minutes and the 
supernatant transferred to a 1.5ml tube. 150μl of 100% ethanol was applied and the 
samples were spun through qiagen columns at 10000 rpm and the flow through was 
removed. DNase stock solution was made up containing DNase and RDD. 350 µl of RW1 
buffer was applied to the spin columns and spun through at 10000 rpm for 15s and the 
flow through was removed. 80µl of RDD/DNase mix was carefully added to the middle of 
the silica matrix of the column for 20 min. This allowed for the digestion of genomic 
DNA. 350μl of RW1 buffer was applied to the spin columns and spun through at 10000 
rpm for 15 s followed by the addition of RPE buffer (500µl) and a 15s spin at 10000 rpm. 
A further spin for 2 min with 80% ethanol (500μl) was carried out and then another spin 
at 13000 rpm for 5 min to ensure the columns were dry. The RNA was then eluted in 14µl 
of DEPC- treated Millipore H2O.  
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2.2.2: Determination of the quantity and quality of the RNA isolated 
The major factor that determines the reliability of the outcome in qPCR is the quality of 
the RNA that is extracted. If RNA is partially degraded then quantification of cDNA 
synthesized from such RNA extract will lead to misleading results as reported by Bustin 
et al (130). Hence, the quality of extracted total RNA was assessed using Agilent 
NanoLabChips run on the Agilent 2100 Bioanalyser. In this method, each nanolab chip is 
pre-poaded with a gel-dye mix to fill the microchannels. 1μl of each RNA sample is 
loaded into one of the 12 wells in the NanoLabChips along with a standard ladder 
(RNA600 ladder). The dye contained within the microchannels intercalates with the RNA 
and an electropherogram plot of the RNA is obtained. This allows the 18S:28S ratio to be 
obtained and provides a numerical value ranging from 1-10 with 1 being most degraded. 
We accepted values over 7 as being indicative of good quality RNA in this study.  
 The concentration of RNA was quantified by using a NanoDrop 1000 
spectrophotometer (Thermo Scientific) which produces accurate readings of RNA 
concentrations from 1μl of sample. This enables equal amounts of RNA to be used as 
templates for the reverse transcription reaction which generates the cDNA.  
 
2.2.3: cDNA synthesis- Reverse Transcription 
530ng of total RNA (based on the NanoDrop quantification) was used in the reverse 
transcription reaction to generate cDNA. This was done using the Superscript III First 
Stand cDNA Synthesis System (Invitrogen) using random hexamer primers as per the 
manufacturer advised protocol. As the efficiency of each RT reaction can vary, all 
samples were reverse transcribed at the same time using the same master mix. The cDNA 
samples thus obtained were diluted in 1 in 35 with molecular biology grade H2O and 
stored at -20°C.  
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2.2.4: qPCR with primers specific for the target mRNA 
Real time qPCR (RT-qPCR) measures fluorescence emitted during the reaction as an 
indicator of the DNA amplified during each cycle (i.e. in real time). The fluorescence is 
generated by a reporter dye which in our case was Power SYBR-green (Applied 
Biosystems). When Power SYBR-green is unbound in the solution, it does not emit any 
fluorescence but when it binds with the minor groove of the double stranded DNA it emits 
strong fluorescent signal. Thus, the intensity of this fluorescence is directly proportional 
to the amount of double stranded DNA present. Recording the amount of fluorescence 
emitted during each cycle enables the monitoring the PCR reaction during the late 
exponential phase where the first detectable increase in the amount of the target template 
occurs. Thus, the greater the starting copy of the cDNA target, the sooner a significant 
increase in fluorescence occurs.  
 
Primers: As we were interested in evaluating the influence of n-3 PUFA on the 
expression of relevant ion channels, transporters and calcium handling proteins, we 
predominantly used commercially available kits (QuantiTect Primer assays) which have 
been tested in human tissue in our laboratory. QuantiTect primer assays are pre-designed 
and tested primer sets that work with power SYBR-green technology and produce reliable 
and accurate results. They eliminate the requirement of developing and optimizing primer 
pairs. However, there were few targets for which we had in-house primers designed and 
tested in human cardiac tissue in previous studies which we used in this study. The 
primers used in this study are listed in table-8. 
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Table-8: Primer assays used for qPCR. 
A) Qiagen QuantiTect primers 
 Target mRNA Qiagen QuantiTect 
primer assay number 
Voltage-gated Na+ channels: Nav1.5 QT00091812 
Navβ1 QT00066080 
Voltage-gated Ca+ channels:
 
Cav1.2 
Cav1.3 
 
 
QT00053480 
QT00076657 
Voltage-gated K+ channels: Kv1.5 QT01003177 
 Kir2.1 QT00001022 
 Kir3.1 QT00030380 
 Kir3.4 QT00070406 
 Kir6.2 QT00068607 
Calcium handling proteins:  
NCX1 
 
QT00075376 
RYR2 QT00018368 
 Phospholamban QT01160761 
 SERCA2a QT00077231 
Adrenergic receptors:   
 β1 QT00204309 
 β2 QT00200011 
Muscarinic receptors:  
M2 
 
QT00092134 
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B) Custom-designed primers  
 
Target 
mRNA 
Accession 
number 
Primer sequence 5´-3´ 
28S M11167 Forward: gttgttgccatggtaatcctgctcagtacg 
Reverse:  ctgacttagaggcgttcagtcataatccc 
Kv4.3 
 
NM_004980 
 
Forward: tggccttctacggcatcct 
Reverse: gctcggcgttctccctct 
Cx40 
 
NM_005266 Forward: gcctcccaacaaaacacagac 
Reverse: cttctggccataacgaacctg 
Cx43 
 
NM_000165 
 
Forward: 5’-3’ tgaagagcatggtaaggtgaaa 
Reverse: 5’-3’ agcaagaaggccacctcaaa 
 
  
PCR Protocol: 10 µl reactions were set-up consisting of 2x Power SYBR-green universal 
PCR master mix (Applied Biosystems), 1µl of cDNA template and 10X Qiagen primer 
assay. The following PCR protocol was used: (i) AmpErase uracil-N-glycosylate 
activation- 2 mins at 50°C (ii) hot start, 10 mins at 95°C (iii) 40 cycles of denaturation-15 
s at 95 °C followed by annealing/extension- 1min at 60°C (iv) dissociation curve- 15s at 
95°C, 15s at 60°C and 15s at 95°C. The PCR reaction was carried out in a MicroAmp 
optical 96-well reaction plate (Applied Biosystems) sealed with an optical cover. Each 
template was tested as a triplicate in the same plate.  
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qPCR quantification: To correct for any variation of RNA input into the Rt reaction, the 
relative abundance for each transcript was normalized to the relative abundance for the 
housekeeper gene. The housekeeper used in this study was 28s subunit and the following 
equation was used to calculate the relative abundance of cDNA in each sample: 
Ry= (Effy)ΔCty / (Effhkg)ΔCthkg 
Where y is the transcript, Ct is the cycle threshold value, R the relative abundance, hkg is 
the house keeper gene, Eff is the average efficiency of the PCR (efficiency of PCR is a 
measure of number of DNA fragments that are copied in a single cycle). The efficiency of 
the PCR reaction is calculated from the fluorescence at the end of each elongation step 
using the following equation:  
Eff = √Fn/F-2n  
Where F is the fluorescence measured and n is the cycle number. 
 
2.3: Immnuohistochemistry 
Immunohistochemistry is a technique used to detect and localize specific antigens in 
tissue sections with the use of antibodies. Primary antibodies react with specific antigens 
and form an antigen-antibody complex. Secondary antibodies that are raised against the 
primary antibodies and conjugated to fluorochromes are used to detect the primary 
antibodies. It is also possible to quantify the fluorescent signal produced by these 
fluorochromes and obtain a semi-quantitative estimate of the abundance of the antigen 
being detected.  
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2.3.1: Antibodies used in immunohistochemistry 
 There are 2 types of anti-bodies- Monoclonal and polyclonal. Monoclonal antibodies are 
produced in a laboratory by a hybridoma or an antibody-producing cell source for specific 
antigen. Polyclonal antibodies are produced by injecting laboratory animals with the 
protein and then collecting serum from these animals. This serum is then purified to 
obtain antibodies for the specific antigen injected into the animal. Consequently, 
polyclonal antibodies react against many regions of the molecule thus giving a stronger 
signal while monoclonal antibodies are specific and may have a weaker signal. Thus, 
polyclonal antibodies are very sensitive to detect small quantities of antigen while 
monoclonal antibodies are very specific.  
 
The antibodies used in this study are listed in table-9. The specificity and reliability of 
most of these anti-bodies have been tested in our laboratory during previous studies using 
human tissue 131.  
 
Table-9: Primary antibodies used in Immunohistochemistry (+/-WB) 
Target protein Host species Company Catalogue number 
PLB-A1  Ms IgG Badrilla A010-14 
NCX1 Ms IgM Affinity BioReagants MA3-926 
RyR2 Ms IgG Affinity BioReagants MA3-916 
SERCA2a Ms IgG Affinity BioReagants MA3-910 
CAV-1 Rabbit IgG Sigma C-3237 
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2.3.2: The immunohistochemistry protocol 
Immnuofluorescence experiments were carried out on 20μm sections cut from frozen 
samples of human right atrial appendage tissue obtained per-operatively from patients. 
The sections were cut using a cryotome and collected on Superfrost Plus glass slides. The 
sections were fixed in 10% neutral buffered formalin (Sigma) and washed three times 
with phosphate buffered saline (PBS). Subsequently, they were permeabilised by 
incubating with PBS containing 0.1% Triton X-100 for 30 mins and ten washed in PBS 
followed by blocking with 1% bovine serum albumin (BSA) in PBS for 1 hour. After 
washing 3 times, the sections were incubated with the primary antibodies overnight at 
room temperature. The primary antibodies were diluted in 1% BSA in PBS and used at a 
dilution of 1:50. The following day, the slides were washed three times in PBS and 
incubated with appropriate secondary antibody (donkey anti-rabbit IgG conjugated to 
CY3 and donkey anti-mouse IgG conjugated to cy3) diluted in PBS in a 1 in 100 dilution 
for 2 hours. Subsequently, slides were washed three times in PBS and sections were 
mounted with Vectashield (Vector Labs) and sealed with cover-slips and nail varnish. 
Slides were stored at 4°C and in the dark for subsequent viewing. Fluorescent signal was 
detected using a confocal microscope (Zeiss LSM5, Carl Zeiss Microscopy) with Pascal 
software (Zeiss Microscopy). The excitation wavelength used was 550 nm for Cy3. Signal 
intensity measurements were then made using Volocity software (Improvision) after 
background correction. 
 
2.4: Western blotting 
The Western blot or protein immunoblot is a technique used to detect specific proteins in 
the given sample of tissue homogenate with the use of gel electrophoresis. The most 
common type of gel electrophoresis uses polyacrylamide gels (PAGE) and buffers loaded 
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with sodium dodecyl sulfate (SDS). Initially the protein homogenate is treated with strong 
reducing agents to remove secondary and tertiary structure (e.g. disulfide bonds [S-S] to 
sulfhydryl groups [SH and SH]) allowing separation of proteins by their molecular 
weight.  SDS-PAGE (SDS polyacrylamide gel electrophoresis) then maintains 
polypeptides in a denatured state and the proteins become covered in the negatively 
charged SDS and move to the positively charged electrode through the acrylamide mesh 
of the gel. Smaller proteins migrate faster through this mesh and the proteins are thus 
separated according to size measured in kilodaltons (kDa). The concentration of 
acrylamide determines the resolution of the gel - the greater the acrylamide concentration 
the better the resolution of lower molecular weight proteins. Lower concentrations of 
acrylamide lead to better resolution of higher molecular weight proteins. In our study, as 
we estimated proteins of variable densities, we used commercially available gels with 
strengths varying from 4% to 10% and frequently a graded gel with multiple strengths 
along the length of the electrophoretic column to enable adequate separation and accurate 
identification.  A typical Western blot reaction consists of the following steps: 
(i) Protein extraction 
(ii) Protein quantification 
(iii) Sample preparation 
(iv) Gel electrophoresis 
(v) Transfer of gel to nitrocellulose membrane 
(vi) Blocking the membrane (to prevent non-specific binding) 
(vii) Treatment with primary antibody 
(viii) Treatment with secondary antibody 
(ix) Detection and quantification of antigen 
(x) Stripping the membrane off the antigen-antibody complex 
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(xi) Re-probing with a housekeeper gene.  
 
2.4.1: Protein extraction 
Frozen human atrial tissue samples were sliced into small cubes using a surgical scalpel 
and transferred into a 15ml falcon tube and 3mls of Radio-Immuno Precipitation Assay 
(RIPA) buffer and several protease inhibitors (constituents listed in table-10) was added. 
The mixture was left in ice and a homogenizer (IKA Ultra-turrax T25) was cleaned with 
ethanol, Milli-Q water and a final wash with RIPA buffer for approximately 10 sec each. 
The tissue was then homogenized by inserting the homogenizer into the falcon tube while 
being kept in ice at a speed of 24000 rpm for 3 x 5 sec. The probe was allowed to cool 
between each burst of homogenization. This was continued until the tissue was fully 
homogenized. Between each sample, any residual tissue pieces on the homogenizer were 
removed with a forceps and the homogenizer was thoroughly cleaned as mentioned 
above.  
 Each sample homogenate was centrifuged at 1000 x g at 2°C for 10 minutes to 
remove un-homogenized tissue bits and residues. The supernatant was then transferred 
into clean falcon tubes and this process repeated following which the final supernatant 
was transferred into clean Eppendorf tubes, aliquoted and stored at -80°C. 
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Table-10: RIPA buffer and protease inhibitors used during extraction of protein 
Substance Concentration 
Phosphate-buffered Saline (PBS)  1xPBS from a 10x stock solution 
Igepal CA360 (non-ionic detergent) 1% 
Sodium deoxycholate 0.5% 
Sodium dodecyl sulphate (SDS) 0.1% 
Protease Inhibitors  
PhenylMethaneSulphonylFluoride 
(PMSF) 
0.1mg/ml 
Sodium orthovanadate 1mM 
Aprotinin 1μg/ml 
Leupeptin 1μg/ml 
 
2.4.2: Protein quantification 
One aliquot from each sample was defrozen by transferring it into a container with ice and 
the protein concentration in that sample was quantified using the Bio-Rad Protein Assay 
kit. This is a colorimetric assay for protein and is based on the Lowry assay method. The 
Lowry protein assay is a biochemical assay for determining the total level of protein in a 
solution. The method combines the reactions of copper ions with the peptide bonds under 
alkaline conditions with the oxidation of aromatic protein residues. The total protein 
concentration is exhibited by a colour change of the sample solution in proportion to 
protein concentration, which can then be measured using colorimetric techniques. Once 
the reaction has taken place (about 15 minutes) the absorbance of each sample was read at 
a wavelength of 750nm using the BioTek ELx 800 Absorbance Microplate Reader and 
BioTek Gen5TM data analysis software which resulted in an objective measure of the 
concentration of protein in each sample. The sample with the lowest concentration was 
used for volume calculations and if any of the samples had such high concentration to 
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require extremely small volumes, such samples were diluted with the addition of RIPA 
buffer. Equal quantities (25μl) (not concentrations) of each sample was mixed to make a 
“control” sample which acted as an internal control and was loaded in one well in 
experiments.  
 
2.4.3:  Sample preparation 
Equal concentrations (50μg) of sample protein mixtures were mixed with 1x laemmli 
sample buffer from a 4x stock solution (table-11) and 5x β-mercaptoethanol and made 
into a final volume of 50μl with RIPA buffer. The bromophenol blue contained within the 
laemmli sample buffer is used as a tracking dye to enable visualization of the protein as it 
runs on the electropheresis gel. The resultant mixtures were then boiled for 5 minutes to 
reduce the disulphide bonds and destabilize the folded structure of the protein.  
 
Table-11: Constituents of Laemmli’s sample buffer 
Substance Concentration 
SDS 0.07M 
Glycerol 0.018M  
4 x Upper gel buffer  50%  
Bromophenol blue 0.01M  
Milli Q H2O Adjust to final volume required 
 
2.4.4: Gel electrophoresis 
As I had difficulty in casting very thin gels that were required to separate heavy proteins, I 
had to resort to commercially available pre-cast gels with strengths ranging from 5%, 
7.5% and some graded strength 4-20% (Bio-Rad Ready gel Tris HCL gel). These were 
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precast polyacrylamide gel containing 10-wells of 30 µl each. The Bio-Rad Mini-Protean 
II Electrophoresis Cell was used for running all the gels. The gels were carefully removed 
from the packaging and assembled in the electrode block and 1x running buffer (see table-
12) was poured into the chamber and the tank. The gels were then loaded with 20μl of the 
protein sample prepared. 5μl of Bio-Rad kaleidoscope pre-stained marker of known 
molecular weight was also added to each gel. The gels were then run at 25V at room 
temperature for 1 hour or until the dye front had reached the bottom of the gel (or 
overnight at 4°C for RYR, individual gel strengths used and running conditions are 
detailed in table 13). Each electrophoresis reaction was run with one well containing a Bio 
Rad marker and one well containing “control” sample. All experiments were done in 
triplicate to minimize error.  
 
Table-12: Constituents of running buffer 
Substance Concentration 
Tris Base 25mM 
Glycine 192mM 
SDS 3.5mM 
Milli Q H2O Adjust to final volume required 
HCL pH to 8.3 
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Table-13: Gel concentrations and running conditions for various proteins of interest 
Protein of 
Interest 
Molecular  
Weight (133-136)  
Type of Gel 
(% separating 
gel) 
Protein  
Concentration 
Running  
time and rate 
of transfer 
NCX 82KDa 
 
7.5% Tris-Hcl  50μg 25volts 
constant volts 
for 1 hour 
SERCA2A 120KDa 4-20% Tris-Hcl 
gradient gel 
50μg 25volts 
constant volts 
for 1 hour 
PLB 22KDa  
(Dimer-11KDa  
Monomer 
5.5KDa) 
15% Tris-HCL 50μg 25volts 
constant volts 
for 30 minutes 
to1 hour 
RYR 550 KDa 4-20% Tris-Hcl 
gradient gel 
50μg 25 volts, 
constant volts, 
overnight. 
 
2.4.5:  Transfer of gel to nitrocellulose membrane 
The protein thus separated in an agarose gel has to be transferred to a membrane to enable 
it to be detected. The commonly used membranes are nitrocellulose and poly vinylidene 
fluoride (PVDF). In this study, I exclusively used nitrocellulose membrane. The 
nitrocellulose membrane was chosen for its superior non-specific protein binding 
properties (i.e. binds all proteins equally well). Protein binding is based upon hydrophobic 
interactions, as well as charged interactions between the membrane and protein. 
Nitrocellulose membranes were also cheaper than PVDF membranes.  The membrane and 
some sponge pads were equilibrated with 1x transfer buffer containing methanol (see 
table-14). Once the gel has completed the electrophoretic reaction, a gel sandwich is made 
which consisted of two sponge pads in the cathode core over which one piece of filter 
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paper was laid and the gel was placed on top of this. The nitrocellulose membrane was 
then placed over the gel and a further filter paper and a sponge were applied on top to 
complete the sandwich. The blot module was closed and placed in the guide rails on the 
lower buffer chamber with a gel tension wedge so that the blot module was locked in 
place. The blot module was then filled with deionised water (milli Q). This serves to 
dissipate the heat produced during the transfer run. The gels were then transferred at 
constant voltage for one hour. This method of transferring the proteins is called 
electroblotting and uses electric current to pull proteins from the gel into the nitrocellulose 
membrane. The protein move from within the gel onto the membrane while maintaining 
the organization they had within the gel. As a result of this "blotting" process, the proteins 
are exposed on a thin surface layer for detection. After transferring, the membranes were 
washed briefly in 1x Tris Buffered Saline with 1% TweenR 20 (TBS-T) (see table-15) to 
remove any gel debris. 
 
Table-14: Constituents of transfer buffer 
Substances Concentrations 
Tris Base  25mM 
Glycine 192mM 
Milli Q H2O Adjust to final volume required 
NaOH pH 8.3 
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Table-15: Constituents of TBS-T 
Substance Concentration 
Tris Base 20mM 
NaCl 150mM 
Tween®20 1% 
Milli Q H2O Adjust to final volume required 
HCL pH to 7.6 
 
2.4.6: Blocking the membrane (to prevent non-specific binding) 
Prior to probing the nitrocellulose membrane with an antibody against the target antigen, 
the membrane has to be blocked to prevent non-specific binding. Blocking of non-specific 
binding is achieved by placing the membrane in a dilute solution of protein - typically 3-
5% Bovine serum albumin (BSA) or non-fat dry milk (5%) in Tris-Buffered Saline (TBS), 
with a detergent such as Tween 20 or Triton X-100. In this study, I used 5% milk as a 
blocking agent. This ensures that the milk protein attaches to the membrane in all places 
where the target proteins have not attached. Thus, when the antibody is added, there is no 
room on the membrane for it to attach other than on the binding sites of the specific target 
protein. This reduces "noise" in the final product of the Western blot, leading to clearer 
results, and eliminates false positives. 
 
2.4.7: Treatment with primary antibody 
After blocking, the membrane was exposed to primary antibodies against the target 
antigen (commercially available antibodies generated in a host species or immune cell 
culture by exposure to the protein of interest was used (see table-9 for details of the 
primary antibodies used).  A dilute solution of primary antibody (5 micrograms/ml), made 
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by mixing small quantity of antibody with Tris Buffered Saline (TBS) was added to the 
membrane and the membrane was incubated under gentle agitation. The antibody solution 
and the membrane were incubated together for variable periods depending on the ease of 
transfer of the given target protein and this varied between 1-hour to overnight incubation. 
Shorter incubation was done at room temperature while longer incubation was done at 
4°C. Generally warmer temperatures are associated with more binding, both specific (to 
the target protein, the "signal") and non-specific ("noise"). 
 
2.4.8: Treatment with secondary antibody 
After treatment with primary antibody, the nitrocellulose membrane was thoroughly 
rinsed with TBS-T for 3-5 times to remove any unbound primary antibody. Subsequently, 
the membrane was exposed to another antibody, directed at a species-specific portion of 
the primary antibody. For example, an anti-mouse secondary will bind to almost any 
mouse-sourced primary antibody and will provide consistent results for detection of the 
binding by the primary anti-body. This is known as a secondary antibody. The 
“secondary” antibody was conjugated to a horseradish peroxidase (HRP) enzyme which 
acts as a reporter enzyme. Horseradish peroxidase-linked secondary was particularly used 
to cleave the chemi-luminescent agent, and the reaction product produces luminescence in 
proportion to the amount of protein.  
 
2.4.9: Detection and quantification of antigen 
The pierce Super Signal West Pico Chemi-luminescent substrate, consisting of a stable 
peroxide buffer and luminol/enhancer solution was used to detect the target proteins. The 
membrane was incubated with 1ml each of the 2 solutions contained in this commercial 
kit for 5 minutes and the target protein was visualized directly in a chemiluminescence-
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compatible digital imaging system. The conjugated HRP enzyme catalyses the 
degradation of the chemiluminescent substrate resulting in signal generation.  
 
2.4.10: Stripping and re-probing with house keeper gene 
The common confounder in quantifying the protein by this technique is error with loading 
resulting in variable quantity of proteins being loaded. This can be assessed and if any 
errors found corrected by stripping the membrane and re-probing with a house keeper 
gene.  The housekeeper gene is a gene which remains constant and the luminescence for 
all the wells should be equal when probed for the house keeper gene. If there were any 
disparity, the value of the protein can be normalized to the housekeeper gene which 
corrects for loading error. In this study, a commercially available stripping agent, Pierce 
Stripping Buffer was used to strip the antibody from the membrane and the membrane 
was reprobed with GAPDH as a house keeping gene. All results were expressed after 
normalizing to GAPDH and to the internal control sample.  
 
2.5: Cell isolation from human right atrial appendage 
I attempted to isolate single atrial myocytes from human atrial appendage tissue obtained 
during CABG surgery. Unfortunately, despite trying various protocols and modification 
of an apparently successful protocol, I was unsuccessful in consistently isolating good 
quality cells that could be used to perform cellular electrophysiological experiments. 
Hence, after trying for over a year, I abandoned this part of the study and decided to 
obtain similar data from animals (4 week old, male Wistar rats), fed a 5% fish oil diet 
(which would mimic the dose of human supplementation) for a period of 4 weeks. The 
protocol used in the attempt to isolate human atrial myocytes is a modification of the 
methods used by Dobrev D et al132 and is detailed below. 
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A portion of the atrial appendage tissue that was removed from study participants was 
immersed in a cold transport solution (see table-16) immediately upon removal from the 
patient. This was washed then free of any blood and epicardial fat and sliced into small 
pieces using a sharp surgical scalpel within few minutes of removal from the patient (in 
the cardiac surgical theatre annex) and re-suspended in fresh cold transport solution. This 
tissue was then taken to a laboratory in the hospital within 10 minutes, where the tissue 
was transferred into a tissue dissociation vessel containing calcium free oxygen-saturated 
isolation solution (see table-17) which was maintained at 35°C and continuously 
oxygenated for 20 minutes.  
Subsequent cell isolation was attempted by an enzymatic digestion technique.  In brief, 
the following enzymes - collagenase type V (350 I.U. ml−1, Sigma) and protease type 
XXIV (4 I.U. ml−1, Sigma) were added to the calcium free isolation solution in the vessel 
containing the tissue. This vessel was maintained at 35°C and continuously oxygenated. 
The vessel was also continuously rocked in a heated bath to improve tissue dispersion.  
This step lasted for 15 minutes. After this step was completed, the samples solution was 
removed and replaced with fresh isolation solution containing only collagenase type V 
(350 I.U. ml−1) for 30 minutes in similar conditions.  
The solution was then replaced by a new enzymatic solution where the collagenase 
concentration was reduced to 175 I.U. ml−1.  During this final step, the supernatant was 
replaced by fresh collagenase solution every 15 min and the dissociation was followed by 
microscopic examination of the collected medium.  
Once cells were identified, the collected solution was centrifuged at 1000rpm for 5 mins 
and the supernatant was removed and replaced by Calcium free Tyrode's solution. The 
Calcium concentration was raised stepwise (50, 100, 200, 500 μM). The isolated cells 
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were kept at room temperature in Tyrode's solution (table-18)and transported to the 
university laboratory for use the same day. 
The cells, which appeared to be healthy on initial microscopy, were calcium intolerant 
and got readily damaged upon exposure to calcium. I tried to modify this protocol with 
varying the concentration of the enzymes used for digestion and attempting to improve 
calcium tolerance by introducing the tissue continuously to a small concentration of 
calcium throughout the isolation process. None of these manoeuvres were successful in 
yielding good quality cells.  
 
Table-16: Constituents of transport solution 
Substance Concentration (mmol) 
NaCl 103 
Kcl 5.4 
CaCl2 1.8 
Lactic acid 286 
NaOH To adjust pH to 7.0 
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Table-17: Constituents of isolation solution 
Substance Concentration (mmol) 
NaCl 120 
Kcl 10 
KH2PO4 1.2 
MgCl2 1.2 
Glucose 10 
HEPES 10 
Taurine 20 
NaOH To adjust pH to 7.2 
 
 
Table-18: Constituents of Normal Tyrode’s solution  
Substance Concentration (mmol) 
NaCl 134 
KCl 4 
CaCl2 1 
MgCl2 1.2 
Glucose 11.1 
Probenecid 2 
NaOH/HCl To adjust pH to 7.2 
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2.5.1: Further attempts at human atrial cell isolation 
As I was unable to isolate good quality cells from human right atrium, I halted the 
recruitment process for the trial with a view to avoid loss of samples from trial patients. I 
then applied for a further ethical permission to perform trial isolation from patients who 
were not enrolled in the study but would undergo routine CABG surgery as right atrial 
appendage tissue was routinely excised during CABG surgery to connect the patients’ 
heart to the extra-corporeal circulation. Such ethical permission was obtained from the 
local (South Manchester) ethics committee. I then used this tissue to try and optimize the 
isolation process with guidance from the researchers in Dresden, Germany (Dr. Dobrev 
and Dr. Ravens) who have significant experience in performing experiments on single 
cardiomyocytes isolated from right atrial appendage tissues. I also visited the lab of 
Dr.Workman and Dr. Rankin at University of Glasgow, UK to observe the procedure of 
single cell isolation from human atrial appendage.  
The consistent finding from the cells isolated in both these experienced centres was that 
the cells were variably depolarised with trans-membrane potentials which were higher 
than usual (around -20 to -40). This was considered to be due to loss of membrane bound 
ion channels during the isolation procedure. I also realised that these centres used these 
cells for experimentation after bringing the trans-membrane potential to physiological 
values by passing a depolarising current. Whilst such a manoeuvre may be acceptable to 
evaluate the effect of a compound acutely applied (by adding to the perfusate), we were 
sceptic about the use of such a technique and in any case, such a method would not allow 
us to compare the effects of a supplemented, incorporated substance such as the n-3 
PUFA in diet. Hence after trying for nearly a year, I decided not to pursue this arm of the 
study and to replace it with animal experiments.  
 
 97
2.6: Animal experiments-methods 
4 week old, male Wistar rats were sourced from Charles River Laboratories (UK) and 
housed in the University of Manchester, biological services facility. Animlas were 
randomly assigned to received feeds supplemented with 5% n-3 PUFA or a standard chow 
(control) for a 4 week period. The researcher was blinded to the feed allocation. On the 
day of the experiment, an animal from one of the 2 groups was transported to a dedicated 
cell preparation room minutes prior to use. The rat was humanely sacrificed via stunning 
followed by cervical dislocation in accordance with the guidelines set by the Home Office 
Animal (Scientific Procedures) act 1986. The whole heart were swiftly removed via a 
thoracotomy and stored in isolation solution (table-19) where it was gently massaged to 
assist blood clearance and to prevent clotting. Subsequently, the heart was cannulated via 
the aorta and attached to a Langendorff apparatus were tissue digestion was carried out by 
means of retrograde perfusion with solutions containing proteolytic and fibrinolytic 
enzymes as detailed below. 
Table-19: Constituents of isolation solution 
Substance Concentration (mmol) 
NaCl 134 
KCl 4 
NaH2PO4 1.2 
Glucose 11.1 
MgSO4 1.2 
HEPES acid 10 
NaOH To adjust pH to 7.34 
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2.6.1: Atrial myocyte isolation- unsuccessful 
I initially attempted to perform the field stimulating experiments using isolated rat atrial 
myocytes. I attempted to isolate atrial myocytes using a protocol that has previously been 
used by our group (Walden A, Trafford A). In this technique, the heart was retrogradely 
perfused (37 °C) at 8 ml-min− 1 with solution A (details below). Once the heart had 
cleared of blood and was showing regular contractions solution B was perfused for 
4 min. Collagenase (Worthington type 1, 0.8 mg.ml− 1) and protease (Sigma type XIV, 
0.08 mg.ml− 1) were then perfused for 10 min in solution C. After enzymatic digestion the 
atria were dissected free from the ventricles and gently agitated in solution C containing 
1% bovine serum albumin at 37 °C and cells filtered through 200 μm nylon gauze and 
centrifuged gently at 40 g for 60 s. The supernatant was discarded and the cells re- 
suspended in solution C and attempted to be used for experimentation. However, despite 
our best efforts, this isolation technique was not yielding good quality cells that were 
calcium tolerant, consistently and we had to abandon this step and move on to performing 
the experiments in isolated rat ventricular myocytes. 
 
Solution A (mmol.L− 1):  NaCl, 130; KCl, 5.4; MgCl2, 1.4; NaH2PO4, 0.4; glucose, 
10; HEPES, 5; creatinine, 10;taurine, 20; CaCl2, 0.5 (pH 7.34 with NaOH).  
 
Solution B (mmol.L− 1):  NaCl, 130; KCl, 5.4; MgCl2, 1.4; NaH2PO4, 0.4; glucose, 
10; HEPES, 5; creatinine, 10; taurine, 20; EGTA, 0.1 (pH 7.34 with NaOH) .  
 
Solution C (mmol.L− 1):  NaCl, 130; KCl, 5.4; MgCl2, 1.4; NaH2PO4, 0.4; glucose, 
10; HEPES, 5; creatinine, 10; taurine, 20; (pH 7.34 with NaOH). 
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2.6.2: Ventricular myocyte preparation 
The Langendorff apparatus consists of a coil into which solutions from measuring 
cylinders within a water bath (Grant Instruments Ltd, UK) maintained at 37°C, enter via a 
Miniplus 3 peristalytic pump (Glison Inc, Wisconsin, USA). Surrounding this coil is a 
water jacket, into which the water bath pumping unit pumps water with the result of 
maintaining a solution temperature of 37°C. The coil terminates at a bubble trap, after 
which solutions may enter the cannula and thus the heart, perfusing the tissue via the 
coronary arteries. Control of solution flow is achieved via a three way tap downstream of 
the peristalytic pump. Tubing upstream of the tap is kept as short as possible to reduce the 
lag time of the desired solution reaching the heart. Before and after each solution, the 
Langendorff apparatus was flushed with ultrapure water from the Milli-Q water 
purification system (Millipore (UK) Ltd). The procedure for myocyte isolation is as 
follows. Two solutions were used for cell isolation 1) a calcium free isolation solution as 
shown in table-19 and 2) a low calcium taurine solution as shown in table-20. Initially, the 
Langendorff apparartus was primed by filling the tubing, coil and bubble trap with 
isolation solution. Bubbles were kept to the minimum so as not to exhaust the bubble trap 
reserves and to reduce the dead space in the system. Following canulation, the heart was 
perfused with isolation solution in order to flush the coronary arteries and heart chambers 
off blood. It is essential to flush all the blood as clotting will prevent perfusion and in 
addition calcium present in the blood can affect the activity of the digestive enzymes 
used. Following the initial washout phase, the heart was perfused with isolation solution 
containing collagenase (Worthington Biochemical Corporation, New Jersey, USA) and 
protease (Type XXIV, Sigma Aldrich) at concentrations of 0.6mg/ml and 0.067mg/ml 
respectively. The digestive solution was allowed to perfuse the heart for a typical duration 
of 7-8 minutes after which the heart was flushed with taurine solution which removed all 
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the residual enzymatic activity. At the end of this digestive process, the heart was 
removed from the Langendorff apparatus and the ventricles were dissected out. The 
ventricles were then transferred into a 20ml beaker containing taurine solution where it 
was gently chopped and the tissue triturated using a truncated Pasteur pipette. The tissue 
was then allowed to settle and the supernatant poured via a fine mesh (Bio-Design Inc, 
New York, USA) into a test tube. This first stage served as the final wash after which the 
tissue was repeatedly processed to extract cells using the same method of finer chopping 
and trituration in a smaller volume of taurine solution. After each processing, the 
supernatant solution was filtered through the fine mesh to collect cells and this was 
repeated 4-5 times so that several suspensions of single cells were obtained.  
 
Table-20: Constituents of taurine solution 
Substance Concentration (mmol) 
NaCl 115 
KCl 4 
NaH2PO4 1.2 
Glucose 11.1 
MgSO4 1.2 
HEPES acid 10 
Taurine 50 
NaOH To adjust pH to 7.34 
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2.6.2: Myocyte storage and dye loading 
After isolation, the cells were re-suspended in taurine solution so as to improve the ratio 
of live cells to debris. The tubes were then inspected for cell quality under an 
epifluorescent inverted binocular microscope (Nikon, UK). Rod shaped, clearly striated 
cells that did not spontaneously oscillate were indicative of good quality cells and test 
tubes containing large number of such cells were chosen for experimentation. 1 ml of cell 
suspension was then loaded with Fluo-3AM (Molecular Probes, Invitrogen, UK).  
The Fluo 3AM indicator was made up with 20% w/v dimethyl sulfoxide 
(DMSO)/pluronic F127 to a stock concentration of 1mM. DMSO solubilises the AM 
ester. Pluronic F127 is a low-toxicity dispersing agent which facilitates cell loading. The 
cells were loaded with 5μM Fluo-3AM for 10 minutes then diluted in tyrodes solution to 
prevent further loading. Cells were allowed to stand for at least 30 minutes for de-
esterification. This allows time for non-specific esterases to cleave the AM ester, releasing 
the free acid form which will remain trapped in the cytoplasm. In addition, 2mM 
Probenecid (Sigma Aldrich, UK) was routinely added to the suspension to prevent Fluo-3 
leaving the cell via anionic sarcolemmal channels. 
 
2.6.3: Experimental set-up 
The experimental solutions were contained within eight glass cylinders attached to the 
perfusion chamber where the cells were situated, via plastic inflow tubes and a solution 
changer with heated tip. Solenoid valves were in place, to allow the flow from the 
different cylinders to be controlled. Prior to experimentation, a mounting chamber (bath) 
was prepared by affixing a cover slip (using silicone grease) over a rectangular aperture in 
a Perspex disc. This assembly was then secured in place on the stage of the inverted 
microscope (Olympus IX71, Japan). The bath was then washed with Normal Tyrode’s 
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solution and an aliquot of loaded cells was then added to the bath and allowed to settle 
down and adhere to the cover slip base of the bath. The solution contained in the well was 
continuously replenished by gravity driven inflow at a rate of 0.6ml/min from the 
superfusion system and removed by an outflow tube connected to a suction pump. 
Approximately 200µl of cell suspension was added to the well each time and allowed to 
settle for five minutes to ensure the cells attached to the glass cover-slip before the 
perfusion system was turned on. This allowed the removal of any unattached cells. 
2.6.4: Field stimulation 
All experiments were carried out in room temperature. Myocytes were field stimulated to 
contract via Ag/AgCl2 electrodes at a fixed frequency of 0.5Hz. The electrodes were 
affixed to the chamber with the ends of the wires placed at opposing sides of the well. The 
electrodes were connected to a constant voltage stimulator Digitimer DS2. The cells were 
visualised using an Olympus x40 U-Apo 340, NA 1.35 oil immersion objective. Using 
field stimulation, systolic calcium transients at control condition (Normal Tyrodes) was 
obtained following which the bath was superfused with a 10mM caffeine containing 
solution which caused release of calcium from the sarcoplasmic reticulum (SR) as 
caffeine greatly increases the open probability of ryanodine receptors and causes the SR 
to empty almost all of the calcium contained within it. The calcium transient thus obtained 
is a reflection the total SR content of calcium. Subsequently, nickel plus caffeine was 
added which evoked calcium transients that allowed for measurements of NCX correction 
factor and fractional contribution of SERCA, NCX and PMCA to calcium removal.  
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Figure-2.2: Experimental set-up for field stimulation (to measure 
fluorescence) 
 
 
2.6.5: Measurement of calcium concentration and cellular 
electrophysiology. 
Autofluorescence: Cells contain molecules which are known to fluoresce when excited 
with UV radiation, in the absence of a fluorescent indicator. The majority of cell auto-
fluorescence originates from mitochondria and lysosomes with the most important 
endogenous fluorophore being nicatinamid adenine dinucleotide phosphate (NADPH) 
coenzymes. This kind of background fluorescence is small compared to that produced by 
the fluorescent indicator. 
 
Calcium quantification derived from fluorescence: In some cases the cells were not 
accurately calibrated to calcium due to a failure to obtain a maximal fluorescence for fluo-
3AM (fmax) measurement at the end of the experiment. Therefore intracellular calcium is 
expressed as F/F0, using the following equation: 
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F/F0 = (F – no cell)/(F0 – no cell) 
 
where F is the raw fluorescence measurement, F0 is fluorescence at diastolic levels and 
the no cell is the background fluorescence. Background fluorescence is determined by the 
measurement of fluorescence in the absence of a cell.  
 
2.6.6: Data analysis 
All data were acquired to the PC using Clampex version 9.2, Axon Instruments Inc., 
USA. The files were exported into a visual basic programme (written ‘in house’) for 
analysis. All graphs were plotted in Sigmaplot version 8.0 (SPSS Inc., USA).All data are 
shown as means ± standard error of the mean (SEM). Statistical significance was 
determined using a Students t-test where appropriate; however data that was not normally 
distributed was transformed by log10 prior to performing a Students t-test. In some cases 
data could not be transformed to achieve a normal distribution and a Mann Whitney Rank 
Sum test was used. A p-value of less than 0.05 was considered significant. 
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CHAPTER-3: RESULTS 
3.1: Clinical outcome 
3.1.1: Demographics and duration of supplementation 
Of the 108 patients recruited into the study, 103 patients completed the study. Fifty-one 
patients were randomly assigned to receive placebo, and 52 received n-3 PUFA. Of the 5 
patients who did not complete the study, 2 died awaiting surgery (both were in the 
placebo arm), 2 had their surgery cancelled, and 1 withdrew consent. There were no 
clinically relevant differences between the 2 groups with respect to baseline variables 
such as demographics, co-morbidities, and other likely confounding factors, as shown in 
table-21. 
 
Table-21:   Baseline characteristics of patients in each treatment group 
Variables Placebo (n=51) n-3 PUFA (n=52) 
Male 82% (42) 77% (40) 
Age; median (IQR), y 68 (64–73) 64 (58–71) 
Body mass index; median 
(IQR), kg/m2 
27.2 (24.9–30.2) 28.3 (26.1–31.5) 
β-blockers 82% (42) 88% (46) 
ACE inhibitors/ARB 88% (45) 79% (41) 
Calcium antagonists 26% (13) 19% (10) 
Statins 98% (50) 98% (51) 
Hypertension 29% (15) 35% (18) 
Diabetes mellitus 16% (8) 13% (7) 
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COPD 10% (5) 8% (4) 
Renal impairment 8% (4) 6% (3) 
Previous myocardial 
infarction 
28% (14) 23% (12) 
Echo LV function, low, 
≤55% 
8% (4) 10% (5) 
Echo LA size, dilated, 
≥2.3 cm/m2 
6% (3) 4% (2) 
Postoperative inotropes 53% (27) 58% (30) 
No. of vessels grafted   
1     8% (4) 6% (3) 
2     39% (20) 33% (17) 
3     49% (25) 56% (29) 
4     4% (2) 6% (3) 
Bypass time; median 
(IQR), min 
72 (34, 245) 88 (25, 245) 
Cross-clamp time; median 
(IQR), min 
50 (20, 130) 61 (19, 126) 
Use of Anti-Arrhythmic 
drugs (Amiodarone) 
7 6 
 
 
 
IQR: interquartile range; ACE: angiotensin-converting enzyme; ARB: angiotensin-
receptor blockers; COPD: chronic obstructive pulmonary disease. 
 
The median duration of therapy before surgery was 17 days (12–20) in the placebo group 
and 16.5 days (13–21) in the n-3 PUFA group, as shown in table 21. 
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3.1.2: Drug compliance and levels of n-3 PUFA 
All participants who completed the study (103 out of 108 recruited) reported good drug 
compliance and this was verified by “pill count” of the returned bottles of the trial agent 
by a clinical pharmacist. In addition, the serum, PBMC and tissue levels of n-3 PUFA 
among the two groups were significantly different with consistently higher levels in all 
the three among those who received n-3 PUFA as shown in table-22. 
 
Table-22: Serum, PBMC and cardiac tissue levels of n-3 PUFA 
Fatty Acid 
 
Time Point 
 
Placebo 
 
n-3 PUFA 
 
P* 
 
Serum EPA 
 
Study entry 1.76 (1.49) 1.51 (0.98) NS 
Serum EPA 
 
Surgery 1.53 (0.74) 2.78 (1.13) <0.001 
Serum DHA 
 
Study entry 3.82 (1.38) 3.79 (1.37) NS 
Serum DHA 
 
Surgery 4.19 (1.29) 5.49 (1.02) <0.001 
PBMC EPA 
 
Study entry 0.76 (0.6) 0.61( 0.41) NS 
PBMC EPA 
 
Surgery 0.67 (0.39) 1.19 (0.51) <0.001 
PBMC DHA 
 
Study entry 2.53 (0.72) 2.34 (0.70) NS 
PBMC DHA 
 
Surgery 2.60 (0.74) 3.16 (0.57) <0.001 
Tissue PC 
EPA 
Surgery 0.69 (0.30) 1.23 (0.50) <0.001 
Tissue PC 
DHA 
Surgery 3.3 (1.1) 4.5 (1.6) 0.007 
Tissue PE EPA 
 
Surgery 1.73 (0.73) 2.7 (1.0) 0.002 
Tissue PE 
DHA 
Surgery 11.6 (3.7) 14.3 (3.9) 0.037 
Values are mean (SD), percent of total fatty acids. *Student t test, unpaired. 
PC:Phosphatidyl choline, PE: Phosphatidyl ethanolamine.  
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3.1.3: Primary clinical outcome 
The primary outcome of interest, which is any AF of more than 30s duration in the 5 days 
following coronary artery bypass surgery occurred in was 49.5% (i.e. 51 patients of 103 
had at least 1 episode of AF ≥30 seconds). This incidence is higher than most previously 
reported incidence even though within the range of the reported values. The reason that 
the overall incidence is high is likely to be due to the robust monitoring for AF rather than 
a true increase in the study subjects.  When individual groups were evaluated, it was noted 
that postoperative AF had occurred in 43% of the placebo group and 56% of the n-3 
PUFA group, with a difference of 13% between the 2 groups (95% confidence interval 
[CI], −6% to 30%; χ2 test; P=0.28) (table-23). This is clearly an unexpected result as the 
patients who were supplemented with n-3 PUFA had higher incidence of AF but it is 
important to note that the difference was not statistically significant and therefore could 
have occurred by chance. All data that was not normally distributed was analysed using a 
non-parametric test (Mann- Whitney U test) and are expressed as inter quartile ranges 
(IQR). 
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Table-23:    Duration of therapy and clinical outcomes 
 Placebo (n=51) n-3 PUFA (n=52) P 
Any AF ≥ 30sec 43% (22) 56% (29) 0.28* 
Clinical AF, % (n) 35% (18) 42% (22) 0.60* 
AF burden; median 
(IQR), % hours 
9.6 (4–20) 13.2 (5–30) 0.49† 
Hospital stay; 
median (IQR), d 
7 (6–10) 8.5 (6–12) 0.49† 
ICU/HDU stay; 
median (IQR), d 
1 (1–2) 1 (1–2) … 
Duration of 
therapy; median 
(IQR), d 
17 (12–20) 16.5 (13–21) … 
Values are median (IQR) for continuous variables, ICU indicates intensive care unit; 
HDU, high-dependency unit. *χ2 test; †Mann–Whitney U test. 
 
The Kaplan-Meier actuarial estimates of the occurrence of the primary end point of AF 
≥30 seconds after CABG are shown in figure-3.1. This represents the time since the 
surgery that a given patient was free from any atrial fibrillation. This again depicts the fact 
that there was no significant difference in the AF-free distribution between the 2 groups 
(log rank test; P=0.26). The AF free survival time started declining about 20 hours after 
surgery and reached a plateau at about 80 hours following surgery again indicating that 
most incidences of AF occurred in day 2 and 3 after surgery. This is in keeping with 
routine clinical observation that AF following surgery occurs most frequently within the 
first 3 days following surgery. In our study, maximal incidence of AF occurred between 
40 to 80 hours after surgery (59%). There were no new episodes of clinical AF after 5 
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days of surgery (after the period of continuous monitoring). However, after the period of 
continuous monitoring, if the patients were still in hospital, they only received a 12 lead 
ECG each day which might not have accurately quantified AF as patients could have had 
short bursts of AF when not having the ECG. Specific questioning of patients about 
symptoms of palpitations did not suggest this to be the case.   
 
Figure 3.1:  Kaplan Meier curve for AF free survival in each group 
 
 
 
 112
3.1.4: Analyses to assess confounding influence of other variables 
As there are several known clinical situations that can pre-dispose individuals to AF we 
performed a Cox proportional hazards regression analysis to assess the confounding effect 
of baseline patient characteristics on the relationship between n-3 PUFA therapy and AF. 
This analysis showed age and number of coronary arteries grafted as the only variables of 
importance in univariate analysis; multivariate analysis, adjusting for these differences, 
confirmed that n-3 PUFA therapy had no effect on the incidence of AF, as shown in 
Table-24. 
Table-24: Multi-variate analysis to assess influence of confounding variables 
Hazard Ratio (95% CI)  
Univariate Multivariate 
Treatment group, PUFA 
 
1.37 (0.79, 2.30) 1.48 (0.84, 2.60); P=0.18 
Sex, male 
 
0.74 (0.39, 1.41)  
Age, y 
 
1.03 (1.001, 1.06) 1.04 (1.002, 
1.07); P=0.036 
β-blockers 
 
0.79 (0.39, 1.63)  
ACE inhibitors/ARB 
 
0.52 (0.27, 1.02)  
Calcium antagonists 
 
0.95 (0.49, 1.85)  
Statins 
 
0.72 (0.10, 5.18)  
Echo LV function, low 
 
1.32 (0.56, 3.10)  
Echo LA size, dilated 
 
1.09 (0.34, 3.50)  
Postoperative inotropes 
 
0.96 (0.55, 1.66)  
No. of vessels grafted 
 
1.56 (1.03, 2.36) 1.51 (0.99, 2.30); P=0.055 
Bypass time, 10 min 
 
1.03 (0.97, 1.09)  
Cross-clamp time, 10 min 1.05 (0.95, 1.15)  
ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blockers. 
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3.1.5: Analysis of secondary outcomes 
i) Clinical incidence of AF 
In addition to monitoring for AF using a continous ECG monitor, we also prospectively 
documented AF as noticed and documented by the clinicians (Anaesthetists, Surgeons, 
ITU physicians and Nurses) in the patients medical and nursing records. This was pre-
defined as one of the secondary end points as this would have relevance to the patient and 
the treating physicians in that these would have been symptomatic episodes of AF which 
often is due to a prolonged or troublesome episode needing specific intervention to correct 
it. We noticed that the overall incidence of clinical (most likely symptomatic or prolonged 
episodes) AF was 38.8%, with no difference between groups (35% in the placebo group 
versus 42% in the n-3 PUFA group; χ2 test;P=0.60). 
 
ii) AF burden 
This is a measure of the amount of time spent in AF by a given patient during his/her 
post-operative period. We estimated this as we felt that the highly sensitive technique that 
we were using to identify AF and the rigid definition (>30s) for an end-point event 
(internationally accepted definition of an AF episode) might lend itself to a possibility that 
a given patient might have spent a very small percentage of time in AF but still qualifying 
as having reached an end point. This again showed that the AF burden was considerable 
in both groups with an average duration of 9.6 [4 to 20] [% hours] in the placebo group 
versus 13.2 [5 to 30] [% hours] in the n-3 PUFA group. This difference between the two 
groups was again not statistically significant (Mann–Whitney U test; P=0.49). Of the 
patients who developed AF, most had reverted to sinus rhythm with or with out treatment. 
2 patients in the n-3 PUFA group and 1 patient in the placebo group were in AF at the 
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time of discharge. All the 3 patients were found to be in AF during the 3 week follow-up 
thus making it persistent AF.  
 
iii) Hospital stay and Intensive Care Unit/High-Dependency Unit stay 
One of the major morbidity associated with developing AF in the post operative period is 
prolonged stay in the high intensity care environment (Intensive/ High dependency care 
units) with the attendant risk of developing iatrogenic (hospital acquired) illnesses and 
increased health care costs. Hence we measured this variable to see if there was a 
difference in this outcome as a result of n-3 PUFA supplementation. In our study we 
noted that the length of hospital stay was not different between groups, with a median 
hospital stay of 7 days (6 to 10 days) for the placebo group and 8.5 days (6 to 12 days) for 
the n-3 PUFA group (Mann–Whitney U test; P=0.49). Similarly, the length of stay in 
intensive care/high dependency care was not different with a median ICU/HDU stay of 1 
day (1 to 2 days) for the placebo group and 1 day (1 to 2 days) for the n-3 PUFA group. 
 
iv) Concentration of C-reactive protein (CRP) in the serum 
CRP is an acute phase protein that is released in the circulation during episodes of active 
systemic inflammation. Highly reactive CRP is a measure of underlying systemic 
inflammation and would be expected to be slightly elevated in the post-operative period. 
As discussed earlier, there is increasing evidence that AF may be an inflammatory disease 
with many inflammatory conditions pre-disposing patients to AF. n-3 PUFA has been 
reported to reduce inflammation in acute inflammatory conditions such as rheumatoid 
arthritis and inflammatory bowel disease. Hence in our study we measured HR-CRP in 
the serum of all patients in samples collected within 24 hours of surgery and on day 3 (48 
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to 72 hours) after surgery. There were no clinically relevant differences in CRP at either 
time point between the 2 groups, as shown in table-25.  
 
Table-25: CRP concentration in the treatment groups 
Time Point   
 
Placebo  
(n=51) 
n-3 PUFA 
(n=52) 
P 
 
Within 24 h of 
surgery, mg/L 
 
32 (2–49) 28.5 (15–38) 0.64 
Day 3 after surgery, 
mg/L 
 
188 (79–226) 187.5 (132–
229) 
0.89 
Values are median (IQR) (Mann-Whitney U test) 
 
3.1.6: Dietary n-3 PUFA Intake 
Dietary intake of n-3 PUFA, particularly of marine source is likely to be a confounder if 
there was a significant difference between the two groups. This has not been adequately 
addressed in most studies using n-3 PUFA supplements. We evaluated this administering 
a food frequency questionnaire which was completed by all the patients who enrolled into 
the study. Assessment of weekly dietary n-3 PUFA consumption was done by computing 
the values for each food item and portion consumed over a week and the total value was 
divided by 7 to obtain average daily n-3 PUFA intake. Such evaluation at baseline did not 
show a difference between the two groups as shown in table-26. 
Table-26: Dietary intake of n-3 PUFA 
Treatment group Dietary EPA+DHA (mg/day) P 
Placebo 118 (31 to 431) 
n-3 PUFA 131 (24 to 524). 
0.86 
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3.1.7: Postoperative Complications 
Post operative complications were evaluated by looking at patient records 4 weeks after 
discharge and any hospital admission in this period was evaluated for causality of the trial 
drug (n-3 PUFA). In accordance with the regulations of the Medicines and Health care 
Regulatory Agency of the UK, all these episodes were reported as adverse events. Three 
patients were hospitalized (2 in the placebo group and 1 in the active treatment group) in 
the 4 weeks after discharge with complications that were deemed unrelated to study 
participation. Two patients (1 in each group) had skin infection over the vein graft site and 
1 (placebo group) had non-cardiac chest pain. 
 
3.1.8: P-wave parameters in the two groups 
The P-wave parameters analysed between the two groups on standard 12 lead ECG did 
not show significant differences at baseline. When evaluated for the effect of the 
intervention (Placebo Vs n-3 PUFA), there was no difference in any of the three p-wave 
parameters studied as a result of n-3 PUFA supplementation as shown in table 27. This is 
in keeping with the clinical outcome data in that n-3 PUFA did not reduce clinical AF.  
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Table-27: Effect of n-3 PUFA supplementation on P-wave parameters 
Treatment group P-max (baseline) P-max (at surgery) p 
Placebo 107.4±10 (ms) 108.1±9.6 0.79 
n-3 PUFA 106.7±10.3 106.4±10.4 0.92 
 P-min (baseline) P-min (at surgery)  
Placebo 80.9±6.6 78.8±7.9 0.48 
n-3 PUFA 79.3±10 80.4±6.8 0.41 
 PWD (baseline) PWD (at surgery)  
Placebo 26.5±9.3 27.9±9.7 0.39 
n-3 PUFA 28.8±11.3 26.0±9.7 0.46 
 
 
3.1.9: HRV in the two groups (3rd post operative day) 
Of the several heart rate variability parameters studied, the n-3 PUFA group showed a 
significantly higher high frequency (HFn) signals in the frequency domain analysis as 
detailed in table 28. This variable correlates with high parasympathetic tone. This 
difference was seen in the analysis of 1-hour recording of pacing and ectopic free traces 
of continuous ECG. 
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Table-28: Differences in HRV between control and n-3PUFA group  
HRV parameter Placebo n-3PUFA p 
SDNNIDX 25.6±17.9 29.9±15.8 0.37 
RMSSD 29.2±36.2 36.5±28.4 0.43 
Triangle index 15.3±7.5 16.0±5.6 0.69 
HFn 36.2±11.4 43.3±13.1 0.04 
LFn 42.3±18.8 34.7±18.8 0.16 
LF/HF 2.0±1.6 1.4±1.3 0.13 
 
 
3.2: Q-PCR results 
Of the 103 patients who were enrolled in the study, frozen right atrial appendage tissue 
from 61 patients (Placebo-31, n-3 PUFA 30) were used for extraction of c-DNA of which 
52 (Placebo-26, n-3 PUFA-26) were used for Q-PCR analysis. An internal control sample 
(tissue obtained from a patient who was not enrolled into the study and who had not taken 
any n-3 PUFA in the 3 month period prior to surgery) was used in the Q-PCR reaction. 
The m-RNA values were expressed as relative expression of c-DNA compared to a house 
keeper gene (28s subunit protein) and an internal control sample (the delta-delta- Ct 
method). The mean values with error margins are shown in table-29 and the functional 
relevance of some the encoded proteins are shown in table-30.  
The relative expression of c-DNA for individual group of ion channels, 
transporters and calcium handling proteins are depicted in figures 3.2 to 3.7. Among the 
calcium handling proteins, significant changes in expression levels were seen in total 
phospholamban with a lower expression in the n-3 PUFA group without a concomitant 
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change in SERCA expression. In addition, there was increased expression of ryanodine 
receptor protein in the n-3 PUFA group. It was noted that there was also a significantly 
higher expression of M2 receptor proteins in the n-3 PUFA group. The changes seen in 
other ion channels and transporters did not reach significance levels. 
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Table-29: Results of Q PCR (m-RNA levels) of various proteins in human RAA 
         ΔΔCt values (mean ± SEM) Target protein 
tested Placebo (n=31) n-3 PUFA (n=30) 
P 
Nav1.5 0.07± 0.01 0.04 ± 0.01 0.12 
Navβ1 0.16±0.03 0.23± 0.05 0.30 
Cav1.2 0.08±0.01 0.13± 0.04 0.22 
Cav1.3 0.11±0.03 0.13± 0.06 0.53 
Kv1.5 0.23 ± 0.04 0.31 ± 0.06 0.29 
Kv4.3 0.10±0.02 0.12±0.03 0.57 
Kir2.1 0.21±0.05 0.33±0.07 0.18 
Kir3.1 0.10±0.02 0.13±0.03 0.37 
Kir3.4 0.21±0.03 0.27±0.08 0.47 
Kir6.2 0.13±0.03 0.18±0.05 0.33 
NCX1 0.17± 0.05 0.26±0.07 0.09 
RYR2 0.11±0.02 0.27± 0.06 0.04 
Phospholamban 0.20±0.04 0.10 ±0.02 0.02 
SERCA2a 0.22 ±0.07 0.20±0.05 0.83 
β1 0.17±0.04 0.13±0.02 0.60 
β2 0.19±0.03 0.25±0.05 0.32 
             M2 0.09±0.02 0.19±0.04 0.03 
Cx40 0.16± 0.04 0.21± 0.04 0.36 
Cx43 0.25 ± 0.05 
 
0.29 ±0.06 0.61 
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Table-30: Functional relevance of changes in m-RNA levels 
Ionic current/ 
Function 
Ion channel  mRNA 
abundance  
ΔΔCt values  
(mean ± SEM) 
(Placebo)  
mRNA 
abundance  
ΔΔCt values  
(mean ± SEM) 
(n-3 PUFA)  
P 
(Unpaired t-test 
(or) Mann 
Whitney U-test) 
INa  Nav1.5 0.07±  0.01 0.04 ± 0.01 0.12 
ICaL  Cav1.2 0.08±0.01  0.13± 0.04  0.22  
Ito  Kv4.3 0.10±0.02  0.12±0.03  0.57  
IKur  Kv1.5  0.23 ± 0.04  0.31 ± 0.06  0.29  
IK1  Kir2.1 0.21±0.05  0.33±0.07  0.18  
IKACH  Kir3.1 0.10±0.02  0.13±0.03  0.37  
IKATP  Kir6.2 0.13±0.03  0.18±0.05  0.33  
INa/Ca NCX1 0.17± 0.05  0.26±0.07  0.30  
SR calcium 
release 
RyR2 0.11±0.02  0.26± 0.07  0.04  
SR calcium 
uptake 
SERCA2a 0.22 ±0.07  0.20±0.05  0.83  
SERCA 
inhibition 
PLB 0.20±0.04  0.10 ±0.02  0.017  
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Figure 3.2: Expression levels of m-RNA of calcium handling proteins 
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Figure 3.3: Expression levels of m-RNA of cardiac connexins 
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Figure 3.4: Expression level of m-RNA of cardiac autonomic receptors 
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Figure 3.5: Expression level of m-RNA of cardiac sodium channels 
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Figure 3.6 (A): Expression level of m-RNA of cardiac potassium 
channels 
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Figure 3.6 (B): Expression level of m-RNA of cardiac potassium 
channels (Ito and IKur) 
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Figure 3.7: Expression level of cardiac calcium channels 
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3.3: Immunohistochemistry-Results 
 
The role of immunohistochemistry was mainly to evaluate the distribution pattern of a 
target protein, however, semi-quantitative estimates of the fluorescence emitted (as 
measured by a specifically designed velocity soft ware package) could be used to evaluate 
the expression level of a given target protein. This method has been reliably used in 
several studies within our group and other workers in this field.  The mean fluorescence 
was measured for calcium handling proteins and is shown in table-31 and figure-3.8. 
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Table-31: Semi-quantitative assessment of expression of calcium 
handling proteins in Immunohistochemistry. 
 
Mean Fluorescence- (mean ± SEM)Target protein 
Placebo (n=8) n-3 PUFA (n=8) 
p 
Caveolin 
 
42.9±1.1 36.5±3.8 0.25 
NCX 
 
55.9±4.17 68.2±4.4 0.07 
SERCA 
 
77.5±3.9 81.3±3.6 0.50 
Phospholamban 
 
80.6±4.5 59.5±2.6 0.002 
RYR-2 
 
70.7±3.1 85.9±3.3 0.01 
 
 
Figure 3.8: Immunofluorescence estimates of calcium handling proteins 
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Figure 3.9: Immunohistochemistry- representative images of caveolin 
expression. 
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Figure 3.10: Immunohistochemistry- representative images of NCX 
expression 
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Figure 3.11: Immunohistochemistry- representative images of SERCA 
expression 
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Figure 3.12: Immunohistochemistry- representative images of 
phospholamban expression 
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Figure 3.13: Immunohistochemistry- representative images of RYR2 
expression 
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3.4: Western blot- Results 
 
In addition to qPCR and immuno-histochemistry, accurate quantification of expression of 
calcium handling proteins was attempted using Western blot technique. The resultant 
chemi-luminescence (a measure of the quantity of the target protein found in a given 
quantity of protein concentrate) was normalised for a loading control to correct for 
pipetting error and was again normalised for an internal control sample which was used in 
all the reactions so that uniformity of measurement between reactions could be ensured. 
The resultant mean values are given in table 32 and figure 3.14.  
 
 
Table 32: Western blot- Expression of calcium handling proteins 
 
 
 
 
 
Placebo (n=8) 
 
n-3 PUFA (n=8) p 
NCX 
 
 
1.01±0.10 1.05±0.14 0.85 
SERCA 
 
 
1.20±0.09 1.13±0.11 0.60 
PLB 
 
 
0.91±0.07 0.70±0.06 0.04 
RYR2 
 
 
0.87±0.12 0.93±0.24 0.83 
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Figure 3.14: Western blot- relative abundance of calcium handling 
proteins 
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Figure 3.15: Western blot- expression of NCX- representative image 
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Figure 3.16: Western blot- expression of SERCA- representative image 
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Figure 3.17: Western blot- expression of PLBA2- representative image 
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Figure 3.18: Western blot- expression of RYR2- representative image 
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3.5: Animal Experiments (isolated rat ventricular myocytes)-
Results 
 
The effect of n-3 PUFA incorporation in the membrane phospholipids on the calcium 
handling properties of these cells were evaluated by performing field stimulated 
experiments on isolated rat ventricular myocytes loaded with fluo-3M (a calcium sensitive 
dye) and compared with similar cells from animals fed a standard chow. The frequency of 
stimulation was 0.5Hz throughout the experiments. 
 
3.5.1: Calcium transient amplitude 
 
Having shown differences in the expression level of calcium handling proteins, we 
proceeded to evaluate the functional relevance of such a change. Unfortunately, we could 
not consistently obtain good quality myocytes from human atrial appendage tissue as 
described in chapter-2. Therefore we performed these experiments on isolated ventricular 
myocytes from rats fed n-3 PUFA supplemented diet and compared it with those fed 
standard chow. Field stimulation experiments were carried out as described before to 
obtain Ca+ transient amplitude of the rat ventricular myocytes. In some cases the cells 
were not accurately calibrated to calcium due to a failure to obtain a maximal 
fluorescence for fluo-3F (Fmax) measurement at the end of the experiment. Therefore, 
intracellular calcium is expressed as F/F0, where F is the fluorescence measurement and 
F0 is fluorescence at diastolic levels, after subtracting background fluorescence. 
Background fluorescence is determined by the measurement of fluorescence in the 
absence of a cell. However, in all the cells where Fmax was available, both actual 
calibration of calcium and F/F0 was estimated. The mean data of the F/F0 estimation of the 
calcium transient amplitude shows that the calcium transient amplitude of the ventricular 
myocytes is not significantly different between the two groups as shown in table-34. (2.44 
± 0.11 in control (n=17) Vs 2.51 ± 0.09 in n-3 PUFA (n=16) (F/F0), P=0.71).  
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Table 33: Amplitude of systolic calcium transient (F/F0) 
 Control n-3 PUFA p 
Ca+ transient 
Amplitude (F/F0) 
2.44 ± 0.11 2.51 ± 0.09 0.71 
 
3.5.2: Rate of decay of systolic calcium transient 
 
The rate of decay of the systolic calcium transient was measured as the time taken to 
decay from 90% of the transient amplitude to 50% of the amplitude. The decay was 
significantly faster in the n-3 PUFA treated ventricular myocytes as shown in table-35 and 
figure 3.19. Rates of decay of the calcium transients were plotted using an exponential 
curve fit with the use of purpose built software (in-house) modified from Microsoft- 
Excel- Visual Basic software package.  A representative curve fit demonstrating a faster 
rate of decay in a n-3 PUFA treated ventricular myocyte compared to a control myocyte is 
shown in figure-3.20.  
 
Table-34: Time taken for the decay of systolic calcium transient from 
90% to 50% amplitude 
 
 Control n-3 PUFA p 
Time to decay 
from 90% to 50% 
transient 
amplitude (mean 
± SEM) 
170.7±47.7 128.7±69.2 0.02 
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Figure 3.19: Rate of decay of systolic calcium transient in n-3 PUFA 
treated myocytes compared to control myocytes 
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Figure 3.20: Representative image showing a faster rate of decay of 
systolic calcium transient in n-3 PUFA treated myocytes.  
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3.5.3: SR calcium content 
 
Application of 10mM caffeine discharges the SR calcium store and a measure of the 
calcium transient thus obtained is an estimate of the SR calcium content. In the same field 
stimulation experiment, following a series of stimulus to obtain a steady systolic transient, 
stimulation was stopped and 10mM caffeine applied as shown in a representative image 
depicted in figure 3.21. The resultant transient was recorded in both groups to assess the 
effect of n-3 PUFA supplementation on the calcium content of the cell as SR is the main 
storage site for intra-cellular calcium. Again, as we did not have Fmax values in some 
experiments, to maintain uniformity of data, F/F0 was used to estimate the amplitude of 
the caffeine transient. This showed that the calcium transient obtained after caffeine 
application was significantly higher in the n-3 PUFA treated cardiomyocytes as shown in 
figure 3.22. The mean values of  F/F0 for the caffeine transients were 4.22±0.86 for the  
control cells Vs 5.61±0.43 for n-3 PUFA treated cells (p=0.03, Student’s t-test) 
 
 
Figure 3.21:  A typical experimental trace (control cell) illustrating 
systolic calcium transients followed by application of 10mM caffeine to 
release total SR calcium and a gradual return to steady state 
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Figure 3.22: Mean amplitude of caffeine transient (F/F0) in n-3 PUFA Vs 
control cells 
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3.5.4: Intracellular and sarcolemmal calcium removal mechanisms. 
Calcium removal occurs via the intracellular calcium pump, SERCA, and through 
sarcolemmal (SL) calcium transporters, NCX and PMCA. Application of caffeine 
completely inhibits SERCA activity and therefore the rate of decay of the calcium 
transient obtained after application of caffeine is a sum of the measure of activity of the 
other 2 transporters- NCX and PMCA. As shown above, the rate of decay (as measured 
by the time taken to decay from 90% to 50% fluorescence) during the normal systolic 
calcium transient is significantly faster in the n-3 PUFA treated cardiomyocytes compared 
with the control myocytes. However the rate of decay of caffeine evoked calcium  
transient (again as measured by the time taken to decay from 90% to 50%) was not altered 
by n-3 PUFA therapy as shown in table-35 and figure 3.23.  
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Table 35: Rate of decay of caffeine transient 
 
 Control n-3 PUFA p 
Time to decay 
from 90% to 50% 
amplitude (mean 
± SEM) 
919.7±70.4 902.7±84.9 0.66 
 
 
 
Figure 3.23: Rate of decay of caffeine evoked calcium transient in n-3 
PUFA treated cells compared to control myocytes. 
 
 
800
840
880
920
960
1000
Control n-3PUFA
90
-5
0 
de
ca
y 
tim
e 
(m
S)
 
 
 
 
 
 
 
 
 
 
 
 
 144
 
 
 
 
 
 
Chapter 4 
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Chapter-4: Discussion 
 
4.1: Clinical Outcomes 
4.1.1 n-3 PUFA and AF following CABG 
The main finding of this study is that short term therapy with n-3 PUFA raises levels of 
EPA and DHA in serum and phospholipids of the cell membranes of circulating PBMC 
and  atrial tissue, but does not reduce the incidence of AF following CABG. It was also 
found that by continuous monitoring of ECG, the overall incidence of significant AF 
episodes (defined as any AF ≥ 30 sec) was higher than most previously published reports 
(21,22). It could be argued that the criteria for diagnosing AF in our study was strict and the 
monitoring robust such that  some patients would have had very brief AF episodes lasting 
for a short duration which would otherwise not have received any attention. If this was 
true, the clinical relevance of such episodes may also be questioned. In order to address 
these issues, we had prospectively planned to look at 2 variables as secondary end points, 
both of which would clearly focus on this question and aim to give an unambiguous 
answer.  
1) AF burden- Defined as the period of time a given patient was in AF in a 24 hour 
period, expressed as a percentage. By this method we were able to identify the 
total duration of AF/day/patient and the shortest of this was 0.7hrs (42 minutes), 
which would clearly have clinical relevance in terms of symptoms and/ or risk of 
thrombo-embolic episodes. In this respect, a recent study evaluating the risk of 
thrombo-embolism in patients with atrial arrhythmias and an implanted device (193) 
(pacemaker or defibrillator) concluded that an AF burden of ≥5.5hrs over a 30 day 
period of monitoring indicated high risk of thrombo-embolic episodes. If we 
extrapolate this to a short duration of monitoring in our patients (5 days) then it 
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would not be unreasonable to suggest that the AF burden seen in the cohort of 
patients who experienced post operative AF could have pre-disposed these patients 
to a high risk of thrombo-embolic strokes even though, fortunately, there were no 
thrombo-embolic events in the entire study group.  
2) The other secondary outcome measure that addressed this issue is that of clinically 
identified (and on most occasions required specific therapy) AF which was 
identified and documented by the treating physician/ surgeon. Whilst the incidence 
of clinically identified and treated AF episodes were fewer than that identified by 
the continuous monitoring, the incidence of such arrhythmic episodes were not 
different between the two groups, further confirming that n-3 PUFA did not exert 
a beneficial effect on the incidence of AF following CABG. 
 
These findings contrast with those of Calo et al.(9), which was the first ever randomized 
clinical trial to evaluate the effect of n-3 PUFA on atrial fibrillation. This study reported a 
significant reduction in AF following CABG. At the inception of our study (2006) the 
study by Calo et al was the only clinical trial that had been published and we powered our 
study to show similar reduction in AF incidence. There were 2 major issues with the 
design of the study by Calo et al 1) It was an open label study with a potential for bias and 
2) The method of arrhythmia monitoring was not robust as they relied on the daily review 
of  a 3 lead ECG stored in the bed side monitor, which has a potential to miss short spells 
of arrhythmias along with a confounding influence of artefacts. Our aim, when we 
designed the study was to overcome these 2 potential limitations by a study that was 
randomised and double blinded along with a robust method for arrhythmia monitoring. In 
addition, we designed the study in such a way that the final outcome of AF will be 
adjudicated by a data monitoring committee who will not be a part of the research team 
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and this committee will review the data prior to recommending that the study should be 
concluded while the researchers were still blinded to the outcome data. At inception of 
our clinical study, we sought to confirm (or refute) the findings of the study by Calo et al 
and to perform cellular studies to evaluate changes at the cellular level that would explain 
such a beneficial/ harmful effect. Through the course of our study, we were aware of 
another study by Heidt et al 137 that was underway addressing the same question in a 
slightly different format. In their study, Heidt et al were administering intra-venous n-
3PUFA suspension following CABG surgery in an open label fashion. In 2009, Heidt et al 
also reported a beneficial effect of n-3 PUFA administration in the immediate post-
operative period however the methodological limitations of the study by Calo et al applied 
to that by Heidt et al in that both studies were open label studies and relied on less robust 
methods of arrhythmia monitoring.  
 
Our findings were in clear contrast with the study by Calo et al and that by Heidt et al in 
that there was no evidence of any benefit with n-3 PUFA therapy and there could have 
been a potential harm but the study sample size was not adequate to conclusively address 
this issue as we had powered the study to show (or not) a benefit of the magnitude seen in 
the study by Calo et al. As our study design was more robust and we had very reliable 
data on the serum and membrane phospholipids levels of n-3 PUFA incorporation, we 
argued that our findings are more reliable. The other issues that could have influenced the 
overall outcome could be patient characteristics and concomitant drug therapy which even 
though was not different between the groups was significantly different from the study 
population in the study by Calo et and Heidt et al. Hence we performed a multiple logistic 
regression analysis to exclude the confounding influence of any of these factors and after 
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such analysis, we could confidently conclude that n-3 PUFA supplementation did not 
reduce the incidence of AF following CABG surgery in our study population.  
 
Another important caveat is the dietary intake of n-3 PUFA as there is some evidence to 
suggest that over all higher dietary intake in some communities could reduce the 
magnitude of the influence of supplements. However, our dietary questionnaire clearly 
demonstrates that our cohort actually had a much lower dietary intake than that reported 
as baseline mean dietary intake in many observational and epidemiological studies (64,76). 
Hence the dietary intake of n-3 PUFA in the overall study population could not have 
reduced the magnitude of beneficial effect in our study population. 
 
4.1.2: Summary of clinical studies on the role of n-3 PUFA in AF 
Since the publication of our study, 2 other studies have addressed the same question in a 
similar study design and have come to the same conclusion in that oral n-3 PUFA 
supplementation did not reduce the incidence of AF following CABG (138,139). These 
studies lend credence to our findings.  
 
A recent meta-analysis by Liu T et al (140) addressed the question of the effect of n-3 
PUFA supplementation on the incidence of AF in 2 different clinical settings  
1) AF following cardiac surgery 
2) Recurrence of AF following cardioversion in patients with clinical persistent AF. 
Data from 10 previously published studies, as shown in table-36, which evaluated the 
effect of n-3 PUFA on either of these two clinical settings was used in this analysis. The 
over all effect of n-3 PUFA supplementation on the incidence of AF of any form was not 
in favour of a beneficial effect.  
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This analysis used 5 clinical trials (of which our study is one) (9,137,138,139 &141) evaluating 
the risk of AF following CABG and convincingly showed that n-3 PUFA therapy did not 
reduce the risk of AF following CABG as shown in Figure 4.1. Interestingly, 2 (9,137) of 
the 5 studies were open label studies and both of them showed a significant reduction in 
the incidence of AF while the other three studies (including our study) were blinded 
studies and clearly demonstrated a lack of benefit. This suggests that observer bias could 
have been an important factor in influencing the outcome of studies that reported a 
beneficial effect.  
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Table 36: Summary of studies on the effect of n-3 PUFA on AF (modified from 
Liu et al). 
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Figure 4.1: Cumulative effect of n-3 PUFA therapy on incidence of AF 
following CABG surgery (from Liu et al) 
 
 
The second clinical setting chosen by the researchers conducting the meta-analysis (Liu T 
et al) was recurrence of AF following reversal to sinus rhythm with external DC 
cardioversion in patients with persistent AF. In this analysis, the researchers evaluated the 
cumulative outcome data from 5 clinical stidues (142-146) and again reported that n-3 PUFA 
did not reduce the recurrence of AF following cardioversion as shown in figure 4.2. 
 
Figure 4.2: Effect of n-3 PUFA on the risk of recurrence of AF (from Liu et al) 
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4.1.3: Monitoring for AF episodes in clinical studies 
An important variable that would have a significant impact on the reported outcome in all 
these studies is the method of arrhythmia monitoring and as discussed in detail above, we 
addressed this issue in a robust fashion in our study. The analysis by Liu et al again 
addressed this question and concluded that there is significant variability in the methods 
used for arrhythmia monitoring within the studies included in this analysis and 
consequently the reported incidence of AF in the control population is very variable as 
shown in table 37.  
 
Table 37: Method of monitoring for AF in studies on the effect of n-3 PUFA on 
AF (Liu et al)  
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4.1.4: Conclusion on the effect of n-3 PUFA in AF following CABG 
Thus our conclusion that n-3 PUFA supplementation pre-operatively does not reduce the 
risk of AF following CABG is well validated. In addition, there appears to be no benefit 
with n-3 PUFA supplementation on the risk of recurrence of AF following cardioversion. 
However, as epidemiological and observational studies (80,147) have shown a reduced 
incidence of new onset AF in individuals with high dietary n-3 PUFA consumption over a 
long period of time, it is relevant to see if longer duration of supplementation in patients 
“at risk” of AF would reduce their chance of developing AF. This question is particularly 
important as one recent report suggests that n-3 PUFA supplementation slows the rate of 
re-modelling of atrial substrate in a heart failure animal model and reduces the risk of new 
onset AF (148). Thus there is still some benefit to be achieved in evaluating the role of n-3 
PUFA in various other clinical settings of AF as n-3 PUFA could be a safe alternative to 
anti-arrhythmic drug therapy with their attendant risk of significant side effects on long 
term administration, in these sub-sets of patient population.  
 
4.1.5: Is Post operative AF a “Good Model” to study AF? 
Atrial fibrillation is a heterogeneous disease that affects various age groups. Often young 
patients (≤35 years) have lone atrial fibrillation in the absence of structural heart disease, 
whereas older individuals (typically ≥65 years) have underlying cardiovascular disorders 
that result in structural remodelling of the atrium, predisposing to atrial fibrillation. It is 
also the most common cardiac arrhythmia reported in clinical practice. Drug treatments 
for this disorder are restricted by pro-arrhythmic effects on the ventricles, and a need 
exists to identify effective drugs that can be used to treat atrial arrhythmias with a 
minimum risk of ventricular arrhythmia. Therefore, the effect of n-3 PUFA on this very 
common arrhythmia deserves further evaluation. The negative finding in our study and 
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several subsequent studies clearly demonstrates the futility of this intervention to prevent 
AF following CABG. However, the pathogenesis of AF following CABG is likely to be 
considerably different from the common forms of AF seen in clinical practice as there are 
factors which are unique to this setting such as 
1) Immune and inflammatory activation due to the surgery 
2) Atrial ischaemia during bypass 
3) Oxidative reperfusion injury 
4) A new scar in the atrium (as a result of atriotomy to connect to the by-pass circuit) 
5) Perturbations of autonomic tone  
6) Concomitant use of adrenergic agents (inotropes) 
 that would not be seen to play a role in the initiation and sustenance of other forms of AF. 
This in addition to findings of a prospective population-based study of adults 65 years, 
where the investigators reported that risk of new onset AF was considerably lowered with 
consumption of grilled or baked fish (147), with a possible dose-response effect that was 
confirmed by measurements of plasma concentrations of eicosapentaenoic acid and 
docosahexaenoic acid and another observational study in men older than 42 years (149), 
which reported that high serum concentrations of docosahexaenoic acid had a protective 
effect against atrial fibrillation during a follow-up of 17 years raised the possibility that n-
3 PUFA may have a beneficial effect in other forms of AF particularly when administered 
over longer periods of time.  
 
4.1.6: Does n-3 PUFA increase the risk of AF? (Pro-arrhythmic 
properties of n-3 PUFA)  
An interesting observation in our study was that patients who received n-3 PUFA had a 
slightly higher incidence of AF episodes. Even though the effect was not statistically 
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significant and could well be a chance association, we could not confidently rule out this 
possibility as this study was powered to look for a beneficial effect of the magnitude 
shown in the previous study by Calo et al. In order for us to have been able to confidently 
rule out a pro-arrhythmic effect (harm from treatment), given the magnitude of the change 
seen in our study, we would have needed a much larger sample size (224 in each group). 
The likelihood of n-3 PUFA exerting a pro-arrhythmic effect in some clinical situations 
(stable angina, ICD recipients) has previously been reported. The cellular basis for such 
an effect has been elaborately reviewed by Den Ruijter et al (51).   
 
4.1.7: AF, Inflammation and n-3 PUFA as an anti-inflammatory agent 
The peak incidence of AF after cardiac surgery coincides with the peak concentration of 
inflammatory indices (150)  and it is well known that the incidence of AF is high in a 
setting of systemic inflammation such as systemic inflammatory response syndrome 
(SIRS) or organ based inflammatory conditions such as pericarditis and pneumonia. In 
keeping with this, statins, drugs with known anti-inflammatory properties, have been 
consistently reported to exhibit some anti-arrhythmic effect in the setting of postoperative 
AF (151).  There is evidence suggesting that fish or n-3 PUFA consumption attenuates 
inflammation and oxidative stress in humans (152, 153).  Thus there is a potential for n-3 
PUFA to have suppressed inflammation and reduced the incidence of AF in the study by 
Calo et al. To specifically address this issue, we estimated the levels of highly sensitive C-
reactive protein (HS-CRP) as a marker of systemic inflammation in our study group. We 
performed estimation of HS-CRP at base line and after 48 hours of surgery (the usual time 
when patients experience peak inflammatory response) in both groups of patients and 
failed to see a significant difference with therapy with n-3 PUFA. This could be because 
the dose used in our study (2g/day) was not sufficient to suppress inflammation as most 
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studies where a significant anti-inflammatory response is seen have used much larger 
doses. Notwithstanding this fact, we could conclude that the beneficial effects reported by 
Calo et al could not have been due to suppression of inflammatory response. 
 
4.1.8: AF, Autonomic regulation and effect of n-3 PUFA on autonomic 
function 
The influence of changes in the autonomic nervous system in the initiation and 
maintenance of paroxysmal AF is well documented (154,155). Electrophysiological 
characteristics of atrial cells (action potential duration and refractoriness, conduction 
speed) are modulated variably by para-sympathetic (vagal) and sympathetic influences 
(156). The former tends to favour macro-reentry phenomena whereas the latter favours 
abnormal automaticity and triggered activity. In normal hearts vagal influences are 
predominant. A common clinical pattern of vagal-mediated paroxysmal atrial fibrillation 
is frequently observed in young, fit adults in the absence of structural heart disease. 
Sympathetically mediated atrial fibrillation is often observed in the presence of structural 
heart disease and common clinical conditions associated with systemic inflammation such 
a pneumonia and pericarditis. The initial effect that is pro-arrhythmic in such situations 
with high sympathetic drive is provocation of a “vagal withdrawal”. Thus, the clinical 
situation in which AF is observed indicates one or the other mechanism to predominate as 
the cause of AF. Often observing the behavior of sinus rate variability (heart rate 
variability-HRV) just preceding the onset of the arrhythmia may permit evaluation of the 
mechanism of arrhythmia. Following cardiac surgery, a heightened sympathetic activation 
and vagal withdrawal are both seen which could contribute to the high incidence of AF in 
this setting (157).  
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Dietary intake of n-3 PUFA have been shown to alter autonomic tone in humans 
(158) with higher n-3 PUFA levels associated with greater para-sympathetic (vagal) tone 
and a slower resting heart rate (160). Several studies have reported that higher dietary 
intake of n-3 PUFA has a significant and consistent influence on the markers of 
autonomic tone such as heart rate variability and other indices of autonomic function with 
the balance being shifted in favor of a cholinergic excess (161-163). This effect could have a 
significant anti-arrhythmic potential particularly in relation to risk of developing 
ventricular arrhythmias and sudden cardiac death. The mechanism of such beneficial 
effect is unclear. None of the studies that showed a beneficial modulation of the 
autonomic tone evaluated the levels of n-3 PUFA in serum and/ or memebrane 
incorporation. As our study design included estimation of all these levels following short 
term supplementaiton, we estimated the influence of n-3 PUFA on various markers of 
autonomic function and compared that with changes at the level of the receptors that 
mediate the cardiac autonomic activity.  
 
 In our study, even though n-3 PUFA supplementation did not reduce the incidence 
of atrial fibrillation following cardiac surgery, we were able to replicate the findings in 
most other clinical situations where n-3 PUFA supplementation had led to a favorable 
modulation of autonomic function with a predominance of cholinergic tone. This was 
evidenced by a higher high frequency signal (a marker of cholinergic dominance) on the 
heart rate variability. Interestingly, we noticed a significant alteration in the expression 
level of cardiac M2 autonomic receptors in the n-3PUFA treated group which might 
sugest a possible mechanism of such beneficial effect as detailed below. 
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4.1.9: Effect of n-3 PUFA on expression of m-RNA levels of cardiac 
autonomic receptors 
 The mechanism by which n-3 PUFA modulate autonomic tone is unclear. The influence 
could be either central within the nervous system or at the receptor level. Considerable 
evidence exists that a change in the lipid composition of biological membranes is closely 
associated with alterations in their function, and in almost all studies with dietary 
supplementation with n-3 PUFAs, an increase in phospholipid EPA and DHA in cell 
membranes has been observed. Often, these alterations in the fatty acid composition leads 
to changes in the expression or affinity of various membrane bound receptor proteins. In 
addition, as discussed above, n-3 PUFA incorporation into cell membranes can lead to 
changes in the membrane fluidity (56), which may in turn alter the dynamics of membrane 
bound enzyme and receptor functions. 
We hypothesised that the beneficial effects of n-3 PUFA seen on the autonomic nervous 
system is likely to be due to a change at the receptor level rather than a central effect on 
the nervous system. We performed qPCR assay for the common cardiac autonomic 
receptors namely β1, β2 and M2 receptors.  This showed that n-3 PUFA supplementation 
and subsequent membrane incorporation was associated with a greater expression of m-
RNA of M-2 muscarinic receptors without a significant change in the expression levels of 
beta-adrenergic receptors. Thus, it is possible that the increased cholinergic response 
observed in many studies and replicated in our study could at least partly be due to a 
higher expression levels of M2 receptors such that for a given cholinergic output there is a 
greater cholinergic response at the end organ level.  
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4.1.10: ECG markers of risk of developing AF and the effect of n-3 
PUFA on these markers: 
P-wave on a surface 12 lead ECG tracing is a reflection of atrial electrical activation. 
Alterations in the properties of P-waves such as maximum duration of P wave (P-max), P 
wave dispersion (PWD-difference between the maximum duration and the minimum 
duration within the 12 leads) have been reported to predict risk of developing new onset 
atrial fibrillation (164). A recent report by Magnani et al (165) on P-wave duration and risk 
for longitudinal atrial fibrillation from the Framingham Heart Study, using a single-
channel electrocardiographic (ECG) recording, found that maximum P-wave duration at 
the upper fifth percentile was associated with long-term AF risk.  
Buxton and Josephson (166) reported that simultaneous recording of ECG leads enables 
calculation of “P-wave dispersion index” -a method of assessing heterogeneity in 
conduction of electrical impulses within regions of the atrium. P-wave dispersion has 
been reported to be a simple ECG predictor of paroxysmal lone AF (164) Although 
acceptable intra-observer and inter-observer error in the measurement of P-wave duration 
on 12-lead electrocardiography have been reported, (164) well-known difficulties in 
defining P-wave onset and offset may restrict the accuracy and reproducibility of the 
measurements. To overcome these restrictions magnified “callipers” on standard 
computer screens have proved useful in the accurate evaluation of common P-wave 
descriptors (167). 
 The effect of n-3 PUFA supplementation on P wave parameters has not been 
reported so far. In this study, we evaluated the P wave parameters in a 12 lead ECG pre 
and post supplementation and compared this with the outcome of atrial fibrillation. We 
showed that short term n-3 PUFA supplementation (with evidence of membrane 
incorporation) did not alter any of the P-wave parameters. This was consistent with our 
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main finding that n-3 PUFA did not reduce the incidence of atrial fibrillation. One 
possible limitation in this aspect of the study could be the fact that there are several 
factors which influence the P wave indices within a given patient (diurnal variation, 
changes with activity levels) (168). However, as all ECGs were done at rest at roughly 
similar time of the day and the strength of randomisation that is inherent in the study 
design would have compensated for this potential confounding influence. Thus, we 
showed that n-3 PUFA supplementation did not have a significant influence on this ECG 
parameter of atrial arrhythmogenesis.  
 
4.1.11: Free and incorporated n-3 PUFA levels and their effect on 
arrhythmias. 
The complex interaction between circulating and tissue levels of n-3 PUFA and the 
resulting electrophysiological alterations are not completely understood and may partly 
explain the variability in results across clinical trials (140,169,170,171). Some effects of n-3 
PUFA that are seen on acute application are not seen after incorporation- particualrly the 
inhibitory effect on sodium channels which is very pronounced in acute application.  
Interestingly, Metcalf et al (172) demonstrated that fish oil supplementation in humans 
causes a gradual increase in tissue levels of n-3 PUFA over few weeks to 2-months, 
whereas plasma levels rise abruptly and remain constant thereafter. Therefore, it is 
possible that the very short term (average of 5 days) administration of n-3 PUFA in the 
study by Calo et al and the Intravenous administration in the study by be Heidt et al could 
have increased the serum levels but not resulted in tissue incorporation. Such increase in 
srum levels without tissue incorportation could mimic acute application in the 
electrophysiological laboratory and may have a more pronounced anti-arrhythmic effect. 
Moreover, there is increasing evidence that local relase of n-3 PUFA from the membrane 
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incorporated phospholipid is necessary for its anti-arrhythmic action and that this effect 
may be dependant on the activity of phospholipase A2 as shown in figure 4.3. 
 
Figure 4.3: A flow diagram of the proposed protective effect of n-3 
PUFA during ischemia. 
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Many studies have reported increased EPA and DHA in plasma or serum lipids 
following supplementation of the diet with n-3 PUFA (173). The increment in these fatty 
acids seen in the current study in serum phospholipids (86% increase in EPA and 45% 
increase in DHA) is consistent with existing data. However, the current study also shows 
higher EPA and DHA in phospholipids of PBMC and atrial tissue after supplementation 
with n-3 PUFA for a relatively short period of time. The higher EPA and DHA content of 
atrial phospholipids after n-3 PUFA supplementation observed in the current study 
supports the observation of Metcalfe et al (172) that these fatty acids, even with short term 
supplementation, are readily incorporated into this tissue. 
In animal experiments, it has been shown that the electrophysiological effects of 
fish oils applied to ventricular myocytes in suspension vary significantly from those of the 
membrane-incorporated n-3 PUFA (51) and this has been reflected by a variable effect of 
acute (often intravenous) vs. chronic (dietary supplementation) administration of n-3 
PUFA on cardiac arrhythmias in man (170). In a clinical setting this would have a bearing 
on the dose, duration and method of administration of n-3 PUFA and the consequent 
variation in circulating and tissue levels of n-3 PUFA. The complex interaction between 
circulating and tissue levels of these fatty acids, the effect of stress on free fatty acid 
release from adipocytes, and the resulting changes in the electrophysiology of 
cardiomyocytes are not well understood and may explain much of the diversity in the 
outcome of clinical studies. In the current study, both the serum and tissue levels of n-3 
PUFA were measured. To our knowledge, this is the first time that tissue levels of n-3 
PUFA have been measured in a clinical study evaluating the anti-arrhythmic potential of 
these fatty acids. 
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4.2: n-3 PUFA and expression level of ion channels, 
transporters and calcium handling proteins 
There is considerable volume of evidence to show that n-3 PUFA influence the effect of 
various cardiac ion channel function in isolated cardiomyocytes both upon acute 
application and incorporation (by dietary supplementation) (51). The effects seem to vary 
with the nature of n-3 PUFA exposure (acute application VS dietary supplementation) and 
there also appears to be a significant inter-species variability. Moreover, the multitude of 
effects makes it difficult to attribute the beneficial anti-arrhythmic property to a specific 
mechanism of action. In addition, n-3 PUFA supplementation changes membrane 
phospholipids composition significantly and the overall fluidity of the membrane seems to 
alter.  Currently there are three plausible mechanisms that have been postulated to explain 
this diverse functional influence on ion channel activity by n-3 PUFA. To date, three main 
hypotheses attempt to explain how n-3 PUFA may exert their influence on cardiac ion 
channels and thus, the electrophysiology of the heart as shown in figure 4.4 (174).  
 
Figure 4.4: Possible mechanisms of action of n-3 PUFA on ion channels 
(from Xiao et al) 
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First, those ion-channels modified by n-3 PUFA may contain a specific binding site for n-
3 PUFA that, if occupied, can alter their function. This is supported by evidence from 
Xiao et al. (175), who showed that a single-point mutation in the alpha subunit of the Na+ 
channel prevented EPA from inhibiting channel currents. This group also showed that co-
expression of the alpha subunits with the beta subunits significantly altered the ability of 
n3 PUFA to affect the channels (176). The second hypothesis is that n-3 PUFA may be 
affecting membrane fluidity and, subsequently, ion channel function. For example, 
Jahangiri et al.(177) correlated the effect of n-3 PUFA on ion channels to changes in 
membrane fluidity by monitoring steady-state fluorescence anisotropy. This hypothesis 
may also explain why n-3 PUFA have such widespread effects on membrane-dwelling 
channels and pumps. However, some argue that the observed effects on ion channels 
occur at much lower concentrations than those necessary to change membrane fluidity. 
Also, the lack of significant effects of n-3 PUFAs on inward rectifier K+ channels (IK1) 
and human hyperpolarization-activated, cyclic nucleotide-gated (hHCN4) channels (178) is 
not along the line of this hypothesis. The third main hypothesis considers that changes in 
the membrane immediately surrounding the channels might be responsible for the ion 
channel effects. The hydrophobic lengths of ion channels are often less than the 
hydrophobic thicknesses of membrane phospholipids, so the membrane must “pinch” 
together around the ion channels. This compression causes tension on the channels and 
affects their function (179). It is considered that n-3 PUFA may insert in the membrane 
around the channels which, in turn, relieves some of the tension by reducing the curvature 
of the membrane. It has been shown that detergents which may relieve tension on ion 
channels induce similar effects to n-3 PUFA (180). However, none of these mechanisms are 
able to explain the overall effect on the ion channels. We therefore hypothesized that n-3 
PUFA may act by altering expression levels of various ion channels, transporters and/ or 
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calcium handling proteins which could then result in the observed functional effect rather 
than a direct inhibitory or excitatory effect. Even though, evidence in relation to alteration 
in the expression levels of these proteins is lacking ( which makes this study interesting 
and relevant), there is some evidence from animal studies to suggest that in dogs fed n-3 
PUFA, the expression levels of cardiac connexins (one of the inter-cellular 
communication channels) is altered significantly. In view of the multitude of functional 
effects seen in animal experiments involving several ion channels, transporters and 
calcium handling proteins, we performed quantitative PCR as a mass screening 
investigation to evaluate for changes in mRNA levels of a number of relevant proteins 
which are potential candidates that could be altered to effect a change in the cardiac 
arrhythmogenesis. 
 
4.2.1: qPCR- mRNA levels of cardiac ion channel proteins 
Using quantitative PCR, we evaluated a number of targets which included sodium 
channels, potassium channels and calcium channels and this revealed that there was no 
significant change in the expression of any of the cardiac ion channel proteins that have 
previously been reported to be showing functional alterations (51,174). This may be due to 
the short duration of supplementation thus not allowing enough time for such alterations 
to be manifest. Of note, most animal studies (Mouse, rats and pigs) that showed a 
functional change upon incorporation used supplementation for periods ranging from 4-16 
weeks, which in a human context could be expected to be much longer. However, in our 
study, we clearly demonstrated a change in the constitution of the membrane 
phospholipids. If the main mechanism of n-3 PUFA on ion channels was indeed mediated 
by an alteration in the expression level of membrane bound ion channel proteins, we 
would have expected to see some difference in the m-RNA levels of those ion channels 
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where animal experiments have previously reported a significant functional alteration. In 
addition, the fact that acutely applied n-3 PUFA could alter functional properties of ion 
channels indicate that n-3 PUFA should be able to exert a direct effect on the ion channels 
themselves rather than altering their membrane expression. 
 
4.2.2: Effect of n-3 PUFA on expression of m-RNA of cardiac connexins 
Gap junctions form the intercellular pathway for cell-to-cell transmission of the cardiac 
impulse from its site of origin, the sinoatrial node, along the atria, the atrioventricular 
conduction system to the ventricular myocardium. The component parts of gap junctions 
are proteins called connexins (Cx), of which three main isoforms are found in the 
conductive and working myocardial cells: Cx40, Cx43, and Cx45. These isoforms are 
regionally expressed in the heart, which suggests a specific role or function of a specific 
connexin in a certain part of the heart. Cx40 is mainly expressed in the atrial myocytes, in 
the AV-node, His-bundle and the ventricular conduction system while Cx43 is by far the 
most abundant and is expressed between atrial and ventricular myocytes and distal parts 
of the conduction system. Cx45 is mostly seen within the cardiac conduction tissue (181). 
The ratio between Cx40 and Cx43 seems to alter conduction properties and has been 
reported to influence the risk of initiation and maintenance of atrial arrhythmias (182). One 
study on dogs with vagal mediated AF reported that n-3 PUFA supplementation altered 
expression of connexin in the dog atria and reduced the risk of vagal mediated AF (183). In 
our study, there was no significant change in the expression levels of cardiac connexins in 
the human right atrium following incorporation of n-3 PUFA in membrane phospholipids. 
Whilst this would suggest that n-3 PUFA may not have an important effect on the cardiac 
connexins, it is important to note that there is considerable variation in the regional 
distribution of connexins and we estimated connexin levels in right atrial appendage. The 
 167
absence of a significant alteration at the RAA does not preclude a change that could have 
manifest in other regions of the atria. Of note, much of the risk of atrial fibrillation is 
linked to alteration in conduction velocities within the left atrium. In addition, the short 
duration of supplementation is also another important factor to be kept in mind while 
deriving conclusions from our finding. Notwithstanding these caveats, our findings 
suggest that short term n-3 PUFA supplementation does not alter the expression levels of 
cardiac connexins in human right atrial appendage.  
 
4.2.3: Effect of n-3 PUFA on expression levels of calcium handling 
proteins 
In our study, we hypothesized that n-3 PUFA supplementation would have a significant 
effect on the expression level of the cardiac calcium handling proteins which could 
explain some of the effects seen above and may translate as a beneficial influence on the 
incidence of AF following CABG. We also sought to evaluate the functional effect on 
cardiac calcium handling in human atrial myocytes after supplementation with n-3 PUFA 
however, due to technical difficulties as described previously, we were unable to do so. 
Hence we estimated the effect of incorporation of n-3 PUFA in rat ventricular myocytes 
to supplement the data obtained in relation to the expression levels of cardiac calcium 
handling proteins. 
qPCR for cardiac calcium handling proteins showed a significant reduction in the 
expression of total phospholamban without a concomitant change in the expression of 
SERCA. Our data also showed a significant increase in the expression level of RYR2 
receptors. There was no change in the expression levels of NCX or SERCA. A similar 
decrease in the expression level of phospholamban and an increase in the expression of 
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RYR2 were shown by using semi-quantitative analysis of fluorescent signals during 
Immunohistochemistry on tissue sections in these patients.  
Western blot analysis to quantify the target proteins involved in cardiac calcium handling 
showed a significant decrease in the quantity of phospholamban however, the increase 
seen in the expression of m-RNA of RYR2 in the qPCR and in the tissue sections by 
Immunohistochemistry was not seen in Western blot analysis. The reason for this lack of 
a significant change in the protein level of RYR2 receptor in the Western blot technique 
while the other two methods suggest a possible increase in the expression could be that 
the sensitivity of the Western blot technique is not high enough to detect a change that 
might be significant. Alternatively, it may also be possible that the change seen in the 
message (as m-RNA) had not translated into a protein level change as the duration of 
supplementation in our cohort was short.  
Notwithstanding this limitation in our data, we could conclude that n-3 PUFA 
supplementation reliably reduced the expression level of cardiac phospholamban in 
human right atrial appendage while it is likely to have had an effect that would translate as 
increased expression of RYR2 receptors.  
 
4.2.4: Alteration in the expression of cardiac phospholamban 
Phospholamban is the major protein that regulates (inhibits) SR calcium ATPase 
(SERCA) activity. The observed reduction in the expression level of cardiac 
phospholamban in the absence of a concomitant change in the SERCA is likely to 
increase the activity of SERCA. This might translate as increased calcium re-uptake into 
the SR and may increase the SR calcium content. As diastolic calcium release is 
predominantly dependant on the cytosolic calcium level, a more effective (or more rapid) 
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re-uptake of cytosolic calcium into the storage site (SR) could suppress diastolic calcium 
release which could be anti-arrhythmic. An important caveat to this discussion relates to 
phosphorylation of phospholamban, which relieves the inhibitory effect of 
phospholamban on SERCA. Unfortunately, within the remit of this study, we were unable 
to measure the phosphorylated phospholamban levels due to lack of time and adequate 
resources. However, in our group, we have previously shown that in rat ventricular 
myocytes perfused with EPA, the rate of phosphorylation of phospholamban was 
significantly increased (194) (4 fold increase). Thus, the only available data on the effect of 
n-3 PUFA on phosphorylation of phospholamban indicates that there is likely to be an 
increase rather than a decrease in the rate of phosphorylation. Hence, the observed effect 
of reduced expression of total phospholamban would lead to a considerable increase in 
SERCA activity if it were to be associated with a concomitant increase in its rate of 
phosphorylation. A concomitant increase in the expression level of RYR2, assuming that 
the expression translates as increased number of “open” RYR2 available (which has 
clearly not been shown in this study as the study by its nature was not designed to test the 
open probability of RYR2) then one could expect a more effective release of calcium 
from the SR and thus a more efficient calcium cycling mechanism. On the contrary, a 
more rapid re-uptake of cytosolic calcium into the SR could lead to SR calcium overload 
that might exceed the threshold for calcium release and could lead to spontaneous release 
of calcium which could be pro-arrhythmic. It is also possible that the observed reduction 
in expression of phospholamban and an increase in the expression level of RYR2 could be 
a compensatory phenomenon to direct inhibition of SERCA and RYR2 respectively, 
which might explain an interesting observation that n-3 PUFA application reduces 
systolic and diastolic calcium transients in heart failure without adversely affecting 
contractility. In summary, the observed changes in the expression level of cardiac 
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phospholamban and RYR2 could have either an anti-arrhythmic or pro-arrhythmic effect 
or it could simply be a compensatory phenomenon and further work is clearly indicated to 
elucidate the functional significance of this finding.  
 
4.3: Effect of n-3 PUFA on calcium handling in rat ventricular myocytes 
In order to correlate the data on the expression level of calcium handling proteins to their 
functional relevance, we used rat ventricular myocytes obtained from rats supplemented 
with n-3 PUFA enriched diet loaded with calcium sensitive dye Fluo-3 and evaluated the 
systolic calcium transient and the response to application of caffeine.  
In our study, we showed that the amplitude of the systolic calcium transient in n-3 PUFA 
supplemented rat ventricular myocytes was not significantly different from that of the 
control cells. This is in contradiction to the data from the study by Den Ruijter et al where 
they reported a significant (>25%) reduction in amplitude of the systolic calcium transient 
upon acute application. However, we showed a much rapid decay of the systolic calcium 
transient in the n-3 PUFA supplemented cells which will co-relate well with increased 
SERCA activity as the function of SERCA is to promote re-uptake of calcium from the 
cytosol into the SR. Upon application of caffeine, the SR empties its entire contents into 
the cytosol and a measure of the amplitude of the calcium transient obtained upon 
application of caffeine is an indirect measure of SR calcium content. Even though there 
are several factors that would need to be considered, not the least, the action potential 
duration, which would have an important effect on the SR calcium content, and we did 
not measure the action potential in our study, we did show that the amplitude of the 
calcium transient obtained after application of caffeine was significantly higher in the n-3 
PUFA treated cells. This could again indicate a greater activity of the SERCA promoting 
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re-uptake of calcium from the cytosol leading to a higher SR calcium content. 
Interestingly, the rate of decay of the caffeine transient was not significantly different 
thereby suggesting that the faster rate of decay of the systolic calcium transient observed 
could indeed be due to greater SERCA activity as SERCA is completely blocked by 
application of caffeine. The other important variable that has not been measured is the L-
type calcium current which would have a bearing on our interpretation of our results.  
In summary, the field stimulation experiments that we carried out shows that n-3 
PUFA incorporation into rat ventricular myocytes does not alter the amplitude of the 
systolic calcium transient but accelerates the decay of the transient. It also increases the 
amplitude of the caffeine transient but does not alter the rate of decay all of which could 
be due to greater SERCA activity which would be consistent with a decreased expression 
level of phospholamban that was shown in all the three modalities of molecular biological 
techniques.  
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4.4: Summary of findings  
1) N-3 PUFA supplementation in the immediate pre-operative period does not reduce 
the risk of AF following CABG surgery. 
2) N-3 PUFA supplementation does not have any effect on the ECG markers of atrial 
arrhythmogenesis 
3) In humans, N-3 PUFA supplementation appears to have a beneficial modulation of 
the cardiac autonomic response with a higher vagal response. This is associated 
with an increased expression level of cardiac M2 receptors in the right atrial 
appendage of patients supplemented with n-3 PUFA. Such increase in expression 
could lead to a situation where a given vagal neural stimulus could produce a 
greater cholinergic response.  
4) N-3 PUFA supplementation reduces the expression level of cardiac 
phospholamban and increases the expression level of cardiac ryanodine receptor in 
human right atrial appendage. 
5) In rat ventricular myocytes, N-3 PUFA supplementation does not alter the systolic 
calcium transient but increases the rate decay of the systolic calcium transient and 
increases the amplitude of the caffeine transient thus indicating a greater re-uptake 
of calcium into the SR and a higher SR calcium content both of which could be 
mediated by a greater activity of SERCA which could be due to lower expression 
of cardiac phospholamban (the inhibitory regulator of SERCA). 
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4.5: Study Limitations 
1) Lack of demonstrable change in the RYR protein by Western Blot 
2) Functional relevance of changes in expression not clearly elucidated 
3) Species difference between human atrium (expression levels) and rat ventricle (calcium 
cycling) 
4) Lack of data on the expression levels in rat ventricular myocytes. 
 
4.6: Future directions: 
4.6.1: Clinical :  
It is clear that n-3 PUFA supplementation does not reduce the risk of AF following 
CABG, however, the role of long term n-3 PUFA supplementation in the primary 
prevention of new onset AF in patients at risk of AF (patients with conditions that are 
known to predispose to AF such as hypertension, heart failure, mitral valve disease etc) is 
not clear and a large clinical trial with a long duration of follow-up will be able to address 
this important and interesting research question as there is an urgent need for a safe and 
effective drug that would prevent AF. 
 
4.6.2: n-3 PUFA, cardiac calcium regulation and AF  
This is the first study to evaluate the expression levels of cardiac ion channels, 
transporters and calcium handling proteins in humans after incorporation of n-3 PUFA. 
The major mechanism of action of n-3 PUFA is still not clear. The findings of this study, 
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whilst generate interesting hypothesis, are not sufficient to address this question 
effectively. It is interesting to note that a short duration of supplementation has indeed 
changed the expression levels of cardiac calcium handling proteins whilst having no 
significant effect on the ion channel expression, this could indicate that much of the anti-
arrhytmic benefits seen in clinical studies following a myocardial infarction and heart 
failure (2 conditions where arrhythmias are precipitated by cellular calcium overload) 
could be due its beneficial influence on cardiac calcium handling. This question is indeed 
very important and can be addressed by a further study evaluating the effect of 
incorporated n-3 PUFA on the calcium handling properties of human ventricular 
myocytes obtained during heart transplant surgery (explanted hearts). This could be 
achieved by selecting patients who are in the elective list for heart transplant and 
supplementing them with oral n-3 PUFA for a period prior to transplant surgery.  
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